

PETER L. KAUFMAN, California State Bar No. 269297

[kaufman@psblaw.com](mailto:kaufman@psblaw.com)

PANISH SHEA & BOYLE LLP

11111 Santa Monica Boulevard, Suite 700

Los Angeles, California 90025

Telephone: 310.477.1700

Facsimile: 310.477.1699

Attorneys for Plaintiff

**UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA**

LLOYD PARSONS,

Plaintiff,

v.

SYNGENTA CROP PROTECTION LLC,  
SYNGENTA AG, and CHEVRON U.S.A.,  
INC.,

Defendants.

Case No.

**COMPLAINT**

**JURY TRIAL DEMANDED**

PANISH SHEA & BOYLE LLP  
11111 Santa Monica Boulevard, Suite 700  
Los Angeles, California 90025  
310.477.1700 phone • 310.477.1699 fax

Plaintiff LLOYD PARSONS, brings this Complaint against Defendants, Syngenta Crop Protection LLC, Syngenta AG, and Chevron U.S.A., Inc., and alleges as follows:

**I. Summary of the case**

1. The manufacturers and sellers of paraquat deliberately concealed the dangers of paraquat for at least four decades, hid evidence of its dangers from government safety agencies, and knowingly released a product they knew caused Parkinson’s Disease on the public.

2. Paraquat is a synthetic chemical compound<sup>1</sup> that since the mid-1960s has been developed, registered, manufactured, distributed, sold for use, and used as an active ingredient in

<sup>1</sup> Paraquat dichloride (EPA Pesticide Chemical Code 061601) or paraquat methosulfate (EPA Pesticide Chemical Code

1 herbicide products (“paraquat products”) developed, registered, formulated, distributed, and sold for  
2 use in the United States (“U.S.”), including the State of Oregon (“Oregon”).

3 3. From approximately May 1964 through approximately June 1981, Imperial Chemical  
4 Industries Limited (“ICI Limited”) and certain ICI Limited subsidiaries<sup>2</sup>, and from approximately  
5 June 1981 through approximately September 1986, Imperial Chemical Industries PLC (“ICI PLC”)  
6 and certain ICI PLC subsidiaries, each of which was a predecessor<sup>3</sup> of Defendants SYNGENTA AG  
7 (“SAG”) and/or Defendants SYNGENTA CROP PROTECTION LLC (“SCPLLC”), were engaged,  
8 directly, acting in concert with each other, and/or acting in concert with Chevron Chemical Company,  
9 previously known as California Chemical Company (“CHEVRON”), in the business of developing,  
10 registering, manufacturing, distributing, and selling paraquat for use as an active ingredient in  
11 paraquat products, and developing, registering, formulating, and distributing paraquat products, for  
12 sale and use in the U.S., including Oregon (“the U.S. paraquat business”).

14 4. From approximately May 1964 through approximately September 1986, CHEVRON,  
15 a predecessor of Defendants CHEVRON U.S.A., INC. (“CUSA”), was engaged, directly and/or  
16 acting in concert with ICI<sup>4</sup>, in all aspects of the U.S. paraquat business.

18 5. Between approximately May 1964 and approximately September 1986, ICI  
19 manufactured and sold to CHEVRON paraquat (“ICI□CHEVRON paraquat”) for use by  
20 CHEVRON, and others to which CHEVRON distributed it, as an active ingredient in paraquat

22 \_\_\_\_\_  
061602).

23 <sup>2</sup> As used in this Complaint, “subsidiary” means a corporation or other business entity’s wholly□owned subsidiary that  
24 is or formerly was engaged in the U.S. paraquat business directly or acting in concert with others.

25 <sup>3</sup> As used in this Complaint, “predecessor” means a corporation or other business entity or subsidiary thereof, to which a  
26 Defendants is a successor by merger, continuation of business, or assumption of liabilities, that formerly was engaged in  
the U.S. paraquat business directly or acting in concert with others.

27 <sup>4</sup> As used in this Complaint, “ICI” means ICI Limited and various ICI Limited subsidiaries through approximately June  
1981 and ICI PLC and various ICI PLC subsidiaries thereafter.

1 products that CHEVRON and others formulated and distributed for sale and use in the U.S., including  
2 Oregon (“ICI □ CHEVRON paraquat products”).

3 6. From approximately September 1986 through the present, ICI PLC and certain ICI  
4 PLC subsidiaries (including predecessors of SCPLLC) initially, then other SAG predecessors and  
5 certain subsidiaries of each (including predecessors of SCPLLC), and most recently SAG and certain  
6 SAG subsidiaries (including SCPLLC), have been engaged, directly and/or acting in concert with  
7 each other, in all aspects of the U.S. paraquat business.

8  
9 7. From approximately September 1986 through the present, ICI PLC and certain ICI  
10 PLC subsidiaries (including predecessors of SCPLLC) initially, then other SAG predecessors and  
11 certain subsidiaries of each (including predecessors of SCPLLC), and most recently SAG and certain  
12 SAG subsidiaries (including SCPLLC), have manufactured paraquat (“ICI □ SYNGENTA paraquat”)  
13 for their own use, and for use by others to which they distributed it, as an active ingredient in paraquat  
14 products that SCPLLC and its predecessors and others have distributed for sale and use in the U.S.,  
15 including Oregon (“ICI □ SYNGENTA paraquat products”).

16  
17 8. Upon information and belief, Plaintiff Lloyd Parsons was exposed to Defendants’  
18 paraquat products in Oregon.

19 9. Upon information and belief, Plaintiff Lloyd Parsons was exposed to Defendants’  
20 paraquat products while working on farms regularly and frequently over a period of many years.

21 10. Today, Plaintiff Lloyd Parsons suffers from Parkinson’s disease caused by many years  
22 of regular, frequent, prolonged exposure to paraquat from Defendants’ paraquat products.

23  
24 11. Plaintiff bring this case to recover from Defendants, under the following theories of  
25 liability, compensation for injuries and damages caused by the exposure of Plaintiff Lloyd Parsons  
26 to paraquat from Defendants’ paraquat products, plus costs of suit: strict product liability—design

1 defect; strict product liability—failure to warn; negligence and willful and wanton conduct; public  
2 nuisance; violation of the Oregon Unlawful Trade Practices Act California Consumer Legal  
3 Remedies Act; and breach of the implied warranty of merchantability. Plaintiff also seek punitive  
4 damages under Oregon common law and punitive damages and reasonable attorney’s fees under the  
5 Oregon Unlawful Trade Practices Act and the California Consumer Legal Remedies Act.

6  
7 12. All allegations contained herein are based upon information and belief and to the best  
8 of Plaintiff’s knowledge given the information currently in Plaintiff’s possession. Plaintiff reserves  
9 the right to amend all allegations upon continued information becoming available by discovery or  
10 otherwise.

11 **II. Parties**

12 **A. Plaintiff**

13 13. Plaintiff Lloyd Parsons is a citizen of the state of Oregon. Plaintiff resides at 1600  
14 Rhododendron Dr., #46, Florence, Oregon 97439.

15 14. Plaintiff Lloyd Parsons was exposed to Defendants’ paraquat products while working  
16 on various farms in Tangent, Oregon.

17 15. Upon information and belief, from 1968 to 2018, Plaintiff Lloyd Parsons was  
18 repeatedly exposed to and inhaled, ingested, and absorbed paraquat while he was mixing, loading,  
19 and, spraying Defendants’ paraquat products and while he was in fields after they were sprayed.

20 21 16. Upon information and belief, each exposure of Plaintiff Lloyd Parsons to paraquat  
22 from Defendants’ paraquat products caused or contributed to cause Plaintiff Lloyd Parsons to  
23 develop Parkinson’s disease, with which he was diagnosed on March 4, 2021 when he was 67 years  
24 of age, by initiating a decades-long process in which oxidation and oxidative stress, created or  
25 aggravated by the ongoing redox cycling of paraquat, damaged and interfered with essential functions  
26

1 of dopaminergic neurons in his SNpc, resulting in the ongoing degeneration and death, as time  
2 passed, of progressively more dopaminergic neurons.

3 17. Upon information and belief, Plaintiff Lloyd Parsons was exposed to paraquat in  
4 Defendants' paraquat products purchased by, among others, Plaintiff Lloyd Parson's employer.

5 18. Defendants and those with whom they were acting in concert manufactured and  
6 distributed the paraquat that was used in formulating Defendants' paraquat products and to which  
7 Plaintiff Lloyd Parsons was exposed, loaded, and distributed Defendants' paraquat products that  
8 contained the paraquat to which Plaintiff Lloyd Parsons was exposed, intending or expecting that  
9 these products would be sold and used in the State of Oregon.  
10

11 19. When Plaintiff Lloyd Parsons was exposed to paraquat, he neither knew nor could  
12 have expected that paraquat was neurotoxic or that exposure to it could cause any neurological injury  
13 or neurodegenerative disease.

14 20. When Plaintiff Lloyd Parsons was exposed to paraquat, he neither knew nor could  
15 have expected that wearing gloves, a mask, or other personal protective equipment or taking any  
16 other precautions might have prevented or reduced the risk of a neurological injury or  
17 neurodegenerative disease caused by exposure to paraquat.  
18

19 21. Plaintiff Lloyd Parsons only recently, within two years of this Complaint being filed,  
20 learned that paraquat caused his injuries. Prior to this, he did not have knowledge of any facts that  
21 would have put him on notice that his Parkinson's Disease was due to Defendants' product nor has  
22 there been widespread media coverage that put him on notice.  
23

24 22. Plaintiff did not know and was unable to learn of the connection between Defendants'  
25 product and his injuries due to the concealment of the information by Defendants and its ongoing  
26

PANISH SHEA & BOYLE LLP  
11111 Santa Monica Boulevard, Suite 700  
Los Angeles, California 90025  
310.477.1700 phone • 310.477.1699 fax

1 campaign stating there is no connection between paraquat and Parkinson's Disease. *See*  
2 [www.paraquat.com](http://www.paraquat.com).

3 **B. Defendants**

4 23. SCPLLC is a Delaware limited liability company with its principal place of business  
5 in Greensboro, North Carolina. SCPLLC is a wholly owned subsidiary of Defendants SAG.

6 24. SAG is a foreign corporation with its principal place of business in Basel, Switzerland.

7  
8 25. CUSA is a Pennsylvania corporation with its principal place of business in San  
9 Ramon, California.

10 **III. Subject matter jurisdiction**

11 26. This Court has subject matter jurisdiction over this action because diversity  
12 jurisdiction exists under 28 U.S.C. § 1332(a)(3).

13 27. The matter in controversy exceeds the sum or value of \$75,000, exclusive of interest  
14 and costs, because Plaintiff seeks an amount that exceeds this sum or value on each of his or her  
15 claims against each Defendant.

16 28. Complete diversity exists because this is an action between citizens of different states  
17 in which a citizen or subject of a foreign state is an additional party, in that:

- 18  
19 a. Plaintiff Lloyd Parsons is a citizen of the State of Oregon;  
20 b. SCPLLC is a citizen of the States of Delaware and North Carolina;  
21 c. CUSA is a citizen of the States of Pennsylvania and California; and  
22 d. SAG is a citizen or subject of the nation of Switzerland.

23  
24  
25 **IV. Personal jurisdiction**

1 29. This Court has personal jurisdiction over each of the Defendants in this diversity case  
2 because a state court in the State of California would have such jurisdiction under Cal. Code Civ.  
3 Proc. § 410.10, in that:

- 4 a. Over a period of two (Chevron) to six (Syngenta) decades, each Defendants and/or its  
5 predecessor(s), together with those with whom they were acting in concert,  
6 manufactured paraquat for use as an active ingredient in paraquat products, distributed  
7 paraquat to formulators of paraquat products, formulated paraquat products, marketed  
8 paraquat products to the California agricultural community, and/or distributed  
9 paraquat products, intending that such products regularly would be, and knowing they  
10 regularly were, sold and used in the State of California;
- 11 b. Plaintiff’ claims against each Defendants arise out of these contacts between the  
12 Defendants and/or its predecessor(s), together with those with whom they were acting  
13 in concert, with the State of California; and
- 14 c. These contacts between each Defendants and/or its predecessors, together with those  
15 with whom they were acting in concert, and the State of California, were so regular,  
16 frequent, and sustained as to provide fair warning that it might be hauled into court  
17 there, such that requiring it to defend this action in the State of California does not  
18 offend traditional notions of fair play and substantial justice.

19 **V. Venue**

20 30. Venue is proper in this district under 28 U.S.C. § 1391(b) because a substantial part  
21 of the events or omissions giving rise to the claim occurred in this district, in that Plaintiff’ claims  
22 arise from injuries caused by the exposure of Plaintiff Lloyd Parsons to paraquat from paraquat  
23 products that were controlled, managed, marketed, developed as described below from this District.

24 **VI. Allegations common to all causes of action**

25 **A. Defendants and their predecessors**

26 **1. Syngenta Crop Protection LLC and Syngenta AG**

27 31. SAG is the successor in interest to the crop□protection business of each of its  
28 predecessors, AstraZeneca PLC (“AstraZeneca”), Zeneca Group PLC (“Zeneca Group”), ICI PLC,

PANISH SHEA & BOYLE LLP  
11111 Santa Monica Boulevard, Suite 700  
Los Angeles, California 90025  
310.477.1700 phone • 310.477.1699 fax

1 ICI Limited, and Plant Protection Limited (“PP Limited”) and their respective crop protection  
2 subsidiaries (collectively, “SAG’s predecessors”), in that:

- 3 a. SAG, and each of SAG’s predecessors, was the result of a corporate name change by,  
4 de facto consolidation or merger of, or mere continuation of, its immediate  
5 predecessor(s); and/or  
6 b. SAG has expressly or impliedly agreed to assume any liability on claims arising from  
7 the historical operation of the crop protection business of each of SAG’s  
8 predecessors

9 32. SCPLLC is the successor in interest to the crop protection business of each of its  
10 predecessors, Syngenta Crop Protection, Inc. (“SCPI”), Zeneca Ag Products, Inc. (“Zeneca Ag”),  
11 Zeneca, Inc. (“Zeneca”), ICI Americas, Inc. (“ICIA”), ICI United States, Inc. (“ICI US”), and ICI  
12 America Inc. (“ICI America”) (collectively, “SCPLLC’s predecessors”), in that:

- 13 a. SCPLLC, and each of SCPLLC’s predecessors, was the result of a corporate name  
14 change by, de facto consolidation or merger of, or mere continuation of, its immediate  
15 predecessor(s); and/or  
16 b. SCPLLC has expressly or impliedly agreed to assume any liability on claims arising  
17 from the historical operation of the crop protection business of each of SCPLLC’s  
18 predecessors.

19 33. At all relevant times, SCPLLC, SCPI, Zeneca Ag, Zeneca, ICIA, ICI US, and/or ICI  
20 America was a wholly owned U.S. crop protection subsidiary of SAG or a predecessor of SAG.

21 34. At all relevant times, PP Limited was a wholly owned U.K. crop protection  
22 subsidiary of ICI Limited, an unincorporated division of ICI Limited, or an unincorporated division  
23 of ICI PLC.

24 35. At all relevant times, SAG and its predecessors exercised a degree of control over  
25 their crop protection subsidiaries so unusually high that these subsidiaries were their agents or alter  
26 egos.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**2. Chevron U.S.A., Inc.**

36. CUSA is the successor in interest to CHEVRON’s crop protection business, in that it has expressly assumed any liability on claims arising from the historical operation of that business.

**B. Defendants’ and their predecessors’ involvement in the U.S. paraquat business**

37. ICI Limited discovered the herbicidal properties of paraquat in the mid 1950s; developed herbicide formulations containing paraquat as an active ingredient in the early 1960s; and produced the first commercial paraquat formulation, which it registered in England and introduced in certain markets under the brand name GRAMOXONE®, in 1962.

38. ICI Limited was awarded a U.S. patent on herbicide formulations containing paraquat as an active ingredient in 1962.

39. In May 1964, ICI Limited, PP Limited, and CHEVRON entered into an agreement for the distribution of paraquat in the U.S. and the licensing of certain paraquat-related patents, trade secrets, and other intellectual property (“paraquat licensing and distribution agreement”).

40. As a result of the May 1964 paraquat licensing and distribution agreement, paraquat became commercially available for use in the U.S. in or about 1965.

41. In April 1975, ICI Limited, ICI US, and CHEVRON entered into a new paraquat licensing and distribution agreement that superseded the May 1964 agreement.

42. In November 1981, ICIA, CHEVRON, and ICI PLC entered into a new paraquat licensing and distribution agreement, effective January 1982, which superseded in part and amended in part the April 1975 agreement.

1 43. From approximately May 1964 through approximately September 1986, pursuant to  
2 these paraquat licensing and distribution agreements, ICI and CHEVRON acted in concert in all  
3 aspects of the U.S. paraquat business.

4 44. In September 1986, ICI and CHEVRON entered into an agreement terminating their  
5 paraquat licensing and distribution agreement.

6 45. Under the September 1986 termination agreement, ICI paid CHEVRON for the early  
7 termination of CHEVRON's rights under their paraquat licensing and distribution agreement.  
8

9 46. Although the September 1986 termination agreement gave ICI the right to buy, or  
10 exchange for ICI-labeled paraquat products, CHEVRON-labeled paraquat products that  
11 CHEVRON had already sold to its distributors, CHEVRON-labeled paraquat products continued to  
12 be sold for use in the U.S. after this agreement for some period of time unknown to Plaintiff.

13 47. SAG, SAG's predecessors, and subsidiaries of SAG and its predecessors (collectively,  
14 "SYNGENTA"), have at all relevant times manufactured more paraquat used as an active ingredient  
15 in paraquat products formulated and distributed for sale and use in the U.S., including Oregon, than  
16 all other paraquat manufacturers combined.  
17

18 48. From the mid-1960s through at least 1986, SYNGENTA (as ICI) was the only  
19 manufacturer of paraquat used as an active ingredient in paraquat products formulated and distributed  
20 for sale and use in the U.S., including Oregon.

21 49. From approximately September 1986 through the present, SYNGENTA has:

- 22
- 23 a. manufactured paraquat for use as an active ingredient in paraquat products formulated  
and distributed for sale and use in the U.S., including Oregon;
  - 24 b. distributed paraquat for use as an active ingredient in paraquat products formulated  
25 and distributed for sale and use in the U.S., including Oregon;
  - 26 c. formulated paraquat products distributed for sale and use in the U.S., including  
27 Oregon; and

1 d. distributed paraquat products for sale and use in the U.S., including Oregon.  
2  
3

4 **C. The use of paraquat products and Defendants' knowledge thereof**

5 50. Defendants' paraquat products have been used in the U.S. to kill broadleafweeds and  
6 grasses before the planting or emergence of more than 100 field, fruit, vegetable, and plantation  
7 crops, to control weeds in orchards, and to desiccate (dry) plants before harvest. At all relevant times,  
8 the use of Defendants' paraquat products for these purposes was intended or directed by or reasonably  
9 foreseeable to, and was known to or foreseen by, SYNGENTA and CHEVRON.  
10

11 51. Defendants' paraquat products were commonly used multiple times per year on the  
12 same ground, particularly when used to control weeds in orchards and in farm fields where multiple  
13 crops are planted in the same growing season or year. At all relevant times, the use of Defendants'  
14 paraquat products in this manner was intended or directed by or reasonably foreseeable to, and was  
15 known to or foreseen by, SYNGENTA and CHEVRON.  
16

17 52. Defendants' paraquat products were typically sold to end users in the form of liquid  
18 concentrates that were then diluted with water in the tank of a sprayer and applied by spraying the  
19 diluted product onto target weeds. At all relevant times, the use of Defendants' paraquat products in  
20 this manner was intended or directed by or reasonably foreseeable to, and was known to or foreseen  
21 by, SYNGENTA and CHEVRON.  
22

23 53. Defendants' paraquat products were typically formulated with a surfactant or  
24 surfactants, and/or a surfactant, surfactant product, or "crop oil," which typically contains one or  
25 more surfactants, was commonly added by users of Defendants' products, to increase the ability of  
26 paraquat to stay in contact with and penetrate the leaves of target plants and enter plant cells. At all  
27

PANISH SHEA & BOYLE LLP  
11111 Santa Monica Boulevard, Suite 700  
Los Angeles, California 90025  
310.477.1700 phone • 310.477.1699 fax

1 relevant times, the use of Defendants' paraquat products as so formulated and/or with such substances  
2 added was intended or directed by or reasonably foreseeable to, and was known to or foreseen by,  
3 SYNGENTA and CHEVRON.

4 54. Knapsack sprayers, hand-held sprayers, aircraft (i.e., crop dusters), trucks with  
5 attached pressurized tanks, and tractor-drawn pressurized tanks, were commonly used to apply  
6 Defendants' paraquat products. At all relevant times, the use of such equipment for that purpose was  
7 intended or directed by or reasonably foreseeable to, and was known to or foreseen by, SYNGENTA  
8 and CHEVRON.  
9

10 **D. Exposure to paraquat and Defendants' knowledge thereof**

11 55. When Defendants' paraquat products were used in a manner that was intended and  
12 directed by or reasonably foreseeable to, and was known to or foreseen by, SYNGENTA and  
13 CHEVRON, persons who used them and others nearby were commonly exposed to paraquat while  
14 it was being mixed and loaded into the tanks of sprayers, including as a result of spills, splashes, and  
15 leaks. At all relevant times, it was reasonably foreseeable to, and known to or foreseen by,  
16 SYNGENTA and CHEVRON that such exposure commonly would and did occur and would and did  
17 create a substantial risk of harm to the persons exposed.  
18

19 56. When Defendants' paraquat products were used in a manner that was intended and  
20 directed by or reasonably foreseeable to, and was known to or foreseen by, SYNGENTA and  
21 CHEVRON, persons who sprayed them, and others nearby while they were being sprayed or when  
22 they recently had been sprayed, commonly were exposed to paraquat, including as a result of spray  
23 drift (the movement of herbicide spray droplets from the target area to an area where herbicide  
24 application was not intended, typically by wind), contact with sprayed plants and being exposed by  
25 paraquat that was absorbed into the soil and ground water and wells. At all relevant times, it was  
26

1 reasonably foreseeable to, and known to or foreseen by, SYNGENTA and CHEVRON, that such  
2 exposure commonly would and did occur and would and did create a substantial risk of harm to the  
3 persons exposed.

4 57. When Defendants' paraquat products were used in a manner that was intended and  
5 directed by or reasonably foreseeable to, and was known to or foreseen by, SYNGENTA and  
6 CHEVRON, persons who used them and other persons nearby commonly were exposed to paraquat,  
7 including as a result of spills, splashes, and leaks, while equipment used to spray it was being emptied  
8 or cleaned or clogged spray nozzles, lines, or valves were being cleared. At all relevant times, it was  
9 reasonably foreseeable to, and was known to or foreseen by, SYNGENTA and CHEVRON that such  
10 exposure commonly would and did occur and would and did create a substantial risk of harm to the  
11 persons exposed.

12 58. At all relevant times, it was reasonably foreseeable to, and was known to or foreseen  
13 by, SYNGENTA and CHEVRON that when Defendants' paraquat products were used in a manner  
14 that was intended and directed by or reasonably foreseeable to, and was known to or foreseen by,  
15 SYNGENTA and CHEVRON, and people were exposed to paraquat as a result, paraquat could and  
16 did enter the human body via absorption through or penetration of the skin, mucous membranes, and  
17 other epithelial tissues, including tissues of the mouth, nose and nasal passages, trachea, and  
18 conducting airways, particularly where cuts, abrasions, rashes, sores, or other tissue damage was  
19 present, and that paraquat that entered the human body in one or more of these ways would and did  
20 create a substantial risk of harm to people so exposed.

21 59. At all relevant times, it was reasonably foreseeable to, and was known to or foreseen  
22 by, SYNGENTA and CHEVRON that when Defendants' paraquat products were used in a manner  
23 that was intended and directed by or reasonably foreseeable to, and was known to or foreseen by,  
24  
25  
26

1 SYNGENTA and CHEVRON, and people were exposed to paraquat as a result, paraquat could and  
2 did enter the human body via respiration into the lungs, including the deep parts of the lungs where  
3 respiration (gas exchange) occurs, and that paraquat that entered the human body in this way would  
4 and did create a substantial risk of harm to people so exposed.

5           60.     At all relevant times, it was reasonably foreseeable to, and was known to or foreseen  
6 by, SYNGENTA and CHEVRON that when Defendants' paraquat products were used in a manner  
7 that was intended and directed by or reasonably foreseeable to, and was known to or foreseen by,  
8 SYNGENTA and CHEVRON, and people were exposed to paraquat as a result, paraquat could and  
9 did enter the human body via ingestion into the digestive tract of small droplets swallowed after  
10 entering the mouth, nose, or conducting airways, and that paraquat that entered the human body in  
11 this way would and did create a substantial risk of harm to people so exposed.

12           61.     At all relevant times, it was reasonably foreseeable to, and was known to or foreseen  
13 by, SYNGENTA and CHEVRON that when Defendants' paraquat products were used in a manner  
14 that was intended and directed by or reasonably foreseeable to, and was known to or foreseen by,  
15 SYNGENTA and CHEVRON, and people were exposed to paraquat as a result, paraquat that entered  
16 the human body via ingestion into the digestive tract could and did enter the enteric nervous system  
17 (the part of the nervous system that governs the function of the gastrointestinal tract), and that  
18 paraquat that entered the enteric nervous system would and did create a substantial risk of harm to  
19 people so exposed.

20           62.     At all relevant times, it was reasonably foreseeable to, and was known to or foreseen  
21 by, SYNGENTA and CHEVRON that when Defendants' paraquat products were used in a manner  
22 that was intended and directed by or reasonably foreseeable to, and was known to or foreseen by,  
23 SYNGENTA and CHEVRON, and people were exposed to paraquat as a result, paraquat that entered  
24  
25  
26

PANISH SHEA & BOYLE LLP  
11111 Santa Monica Boulevard, Suite 700  
Los Angeles, California 90025  
310.477.1700 phone • 310.477.1699 fax

1 the human body, whether via absorption, respiration, or ingestion, could and did enter the  
2 bloodstream, and that paraquat that entered the bloodstream would and did create a substantial risk  
3 of harm to people so exposed.

4 63. At all relevant times, it was reasonably foreseeable to, and was known to or foreseen  
5 by, SYNGENTA and CHEVRON that when Defendants' paraquat products were used in a manner  
6 that was intended and directed by or reasonably foreseeable to, and was known to or foreseen by,  
7 SYNGENTA and CHEVRON, and people were exposed to paraquat as a result, paraquat that entered  
8 the bloodstream could and did enter the brain, whether through the blood-brain barrier or parts of  
9 the brain not protected by the blood-brain barrier, and that paraquat that entered the brain would  
10 and did create a substantial risk of harm to people so exposed.

11 64. At all relevant times, it was reasonably foreseeable to, and was known to or foreseen  
12 by, SYNGENTA and CHEVRON that when Defendants' paraquat products were used in a manner  
13 that was intended and directed by or reasonably foreseeable to, and was known to or foreseen by,  
14 SYNGENTA and CHEVRON, and people were exposed to paraquat as a result, paraquat that entered  
15 the nose and nasal passages could and did enter the brain through the olfactory bulb (a part of the  
16 brain involved in the sense of smell), which is not protected by the blood-brain barrier, and that  
17 paraquat that entered the olfactory bulb would and did create a substantial risk of harm to people so  
18 exposed.

19 65. At all relevant times, it was reasonably foreseeable to, and was known to or foreseen  
20 by, SYNGENTA and CHEVRON that when Defendants' paraquat products were used in a manner  
21 that was intended and directed by or reasonably foreseeable to, and was known to or foreseen by,  
22 SYNGENTA and CHEVRON, and people were exposed to paraquat products that contained  
23 surfactants or had surfactants added to them, the surfactants would and did increase the toxicity of  
24  
25  
26

1 paraquat toxicity to humans by increasing its ability to stay in contact with or penetrate cells and  
2 cellular structures, including but not limited to the skin, mucous membranes, and other epithelial and  
3 endothelial tissues, including tissues of the mouth, nose and nasal passages, trachea, conducting  
4 airways, lungs, gastrointestinal tract, blood-brain barrier, and neurons, and that this would and did  
5 increase the already substantial risk of harm to people so exposed.

6 **E. Parkinson’s disease**

7  
8 66. Parkinson’s disease is a progressive neurodegenerative disorder of the brain that  
9 affects primarily the motor system, the part of the central nervous system that controls movement.

10 67. The characteristic symptoms of Parkinson’s disease are its “primary” motor  
11 symptoms: resting tremor (shaking movement when the muscles are relaxed), bradykinesia (slowness  
12 in voluntary movement and reflexes), rigidity (stiffness and resistance to passive movement), and  
13 postural instability (impaired balance).

14 68. Parkinson’s disease’s primary motor symptoms often result in “secondary” motor  
15 symptoms such as freezing of gait; shrinking handwriting; mask-like expression; slurred,  
16 monotonous, quiet voice; stooped posture; muscle spasms; impaired coordination; difficulty  
17 swallowing; and excess saliva and drooling caused by reduced swallowing movements.

18 69. Non-motor symptoms—such as loss of or altered sense of smell; constipation; low  
19 blood pressure on rising to stand; sleep disturbances; and depression—are present in most cases of  
20 Parkinson’s disease, often for years before any of the primary motor symptoms appear.

21 70. There is currently no cure for Parkinson’s disease; no treatment will stop or reverse  
22 its progression, and the treatments most commonly prescribed for its motor symptoms tend to become  
23 progressively less effective, and to cause unwelcome side effects, the longer they are used.  
24  
25  
26  
27



1           71.     The selective degeneration and death of dopaminergic neurons (dopamine-producing  
2 nerve cells) in a part of the brain called the substantia nigra pars compacta (“SNpc”) is one of the  
3 primary pathophysiological hallmarks of Parkinson’s disease.

4           72.     Dopamine is a neurotransmitter (a chemical messenger that transmits signals from one  
5 neuron to another neuron, muscle cell, or gland cell) that is critical to the brain’s control of motor  
6 function (among other things).

7           73.     The death of dopaminergic neurons in the SNpc decreases the production of  
8 dopamine.

9           74.     Once dopaminergic neurons die, they are not replaced; when enough dopaminergic  
10 neurons have died, dopamine production falls below the level the brain requires for proper control of  
11 motor function, resulting in the motor symptoms of Parkinson’s disease.

12           75.     The presence of Lewy bodies (insoluble aggregates of a protein called alpha-synuclein)  
13 in many of the remaining dopaminergic neurons in the SNpc is another of the primary  
14 pathophysiological hallmarks of Parkinson’s disease.

15           76.     Dopaminergic neurons are particularly susceptible to oxidative stress, a disturbance  
16 in the normal balance between oxidants present in cells and cells’ antioxidant defenses.

17           77.     Scientists who study Parkinson’s disease generally agree that oxidative stress is a  
18 major factor in—if not the precipitating cause of—the degeneration and death of dopaminergic  
19 neurons in the SNpc and the accumulation of Lewy bodies in the remaining dopaminergic neurons  
20 that are the primary pathophysiological hallmarks of Parkinson’s disease.

21           **F. Paraquat’s toxicity**

22           78.     Paraquat is highly toxic to both plants and animals because it causes and contributes  
23 to cause the degeneration and death of living cells in both plants and animals.

1 79. Paraquat causes and contributes to cause the degeneration and death of plant and  
2 animal cells both directly, through oxidation, and indirectly, through oxidative stress created or  
3 aggravated by the “redox cycling” of paraquat; these processes damage lipids, proteins, and nucleic  
4 acids, molecules that are essential components of the structures and functions of living cells, and  
5 interfere with cellular functions—in plant cells, with photosynthesis, and in animal cells, with cellular  
6 respiration—that are essential to cellular health.

7  
8 80. In both plant and animal cells, paraquat undergoes redox cycling that creates or  
9 aggravates oxidative stress because of the “redox properties” inherent in paraquat’s chemical  
10 composition and structure: paraquat is both a strong oxidant and has a high propensity to undergo  
11 redox cycling, and to do so repeatedly, in the presence of a suitable reductant and molecular oxygen,  
12 both of which are present in all living cells.

13 81. The redox cycling of paraquat in living cells creates a “reactive oxygen species”  
14 known as superoxide radical, an extremely reactive molecule that can and often does initiate a  
15 cascading series of chemical reactions that can and often do create other reactive oxygen species that  
16 damage lipids, proteins, and nucleic acids, molecules that are essential components of the structures  
17 and functions of living cells.

18  
19 82. Because the redox cycling of paraquat can repeat indefinitely in the conditions  
20 typically present in living cells, a single molecule of paraquat can trigger the production of countless  
21 molecules of destructive superoxide radical. After even a tiny amount of paraquat enters the human  
22 brain, paraquat molecules continue to undergo redox cycling and continue to cause damage to human  
23 brain cells. This repeated cycling continues in the presence of oxygen and continues to cause the death  
24 of dopaminergic neurons, eventually resulting in the onset of Parkinson’s disease. However, even  
25  
26  
27

1 after the onset of Parkinson’s disease, the redox cycling continues to cause brain cell damage and  
2 death for as long as the victim lives.

3 83. The oxidation and redox potentials of paraquat have been known to science since at  
4 least the 1930s, and in the exercise of ordinary care should have been known, and were known, to  
5 SYNGENTA and CHEVRON at all relevant times.

6 84. That paraquat is highly toxic to all living cells—both plant cells and all types of animal  
7 cells—has been known to science since at least the mid-1960s, and in the exercise of ordinary care  
8 should have been known, and was known, to SYNGENTA and CHEVRON at all relevant times.

9 85. The high toxicity of paraquat to living cells of all types creates a substantial risk of  
10 harm to persons exposed to paraquat, which SYNGENTA and CHEVRON should have known in  
11 the exercise of ordinary care, and did know, at all relevant times.

12 86. The same oxidation and redox potentials that make paraquat highly toxic to plant cells  
13 and other types of animal cells make paraquat highly toxic to nerve cells, including dopaminergic  
14 neurons, and create a substantial risk of neurotoxic harm to persons exposed to paraquat.  
15 SYNGENTA and CHEVRON should have known this in the exercise of ordinary care, and did know  
16 this, at all relevant times.

17 **G. Paraquat and Parkinson’s disease**

18 87. The scientific community overwhelmingly agrees that paraquat causes Parkinson’s  
19 disease.

20 88. Although Parkinson’s disease is not known to occur naturally in any species other  
21 than humans, Parkinson’s disease research is often performed using “animal models,” in which  
22 scientists artificially produce in laboratory animals’ conditions that show features characteristic of  
23 Parkinson’s disease in humans.  
24  
25  
26

1 89. Paraquat is one of only a handful of toxins that scientists use to produce animal models  
2 of Parkinson’s disease.

3 90. In animal models of Parkinson’s disease, hundreds of studies involving various routes  
4 of exposure have found that paraquat causes the degeneration and death of dopaminergic neurons in  
5 the SNpc, other pathophysiology consistent with that seen in human Parkinson’s disease, and motor  
6 deficits and behavioral changes consistent with those commonly seen in human Parkinson’s disease.

7 91. Hundreds of *in vitro* studies (experiments in a test tube, culture dish, or other  
8 controlled experimental environment) have found that paraquat causes the degeneration and death of  
9 dopaminergic neurons.

10 92. Many epidemiological studies (studies of the patterns and causes of disease in defined  
11 populations) have found an association between paraquat exposure and Parkinson’s disease,  
12 including multiple studies finding a two- to five-fold or greater increase in the risk of Parkinson’s  
13 disease in populations with occupational exposure to paraquat compared to populations without such  
14 exposure.

15  
16  
17 **H. Paraquat regulation**

18 93. The Federal Insecticide, Fungicide, and Rodenticide Act (“FIFRA”), 7 U.S.C. § 136  
19 *et seq.*, which regulates the distribution, sale, and use of pesticides within the U.S., requires that  
20 pesticides be registered with the EPA prior to their distribution, sale, or use, except as described by  
21 FIFRA. 7 U.S.C. 136a(a).

22 94. As part of the pesticide registration process, the EPA requires, among other things, a  
23 variety of tests to evaluate the potential for exposure to pesticides, toxicity to people and other  
24 potential non-target organisms, and other adverse effects on the environment.

1 95. As a general rule, FIFRA requires registrants—not the EPA—to perform health and  
2 safety testing of pesticides, and the EPA generally does not perform such testing.

3 96. The EPA registers (or re-registers) a pesticide if it believes, based largely on studies  
4 and data submitted by the registrant, that:

- 5 a. its composition is such as to warrant the proposed claims for it, 7 U.S.C. §  
6 136a(c)(5)(A);
- 7 b. its labeling and other material required to be submitted comply with the requirements  
8 of FIFRA, 7 U.S.C. § 136a(c)(5)(B);
- 9 c. it will perform its intended function without unreasonable adverse effects on the  
10 environment, 7 U.S.C. § 136a(c)(5)(C); and
- 11 d. when used in accordance with widespread and commonly recognized practice it will  
12 not generally cause unreasonable adverse effects on the environment, 7 U.S.C. §  
13 136a(c)(5)(D).

14 97. FIFRA defines “unreasonable adverse effects on the environment” as “any  
15 unreasonable risk to man or the environment, taking into account the economic, social, and  
16 environmental costs and benefits of the use of any pesticide.” 7 U.S.C. § 136(bb).

17 98. Under FIFRA, “As long as no cancellation proceedings are in effect registration of a  
18 pesticide shall be prima facie evidence that the pesticide, its labeling and packaging comply with the  
19 registration provisions of [FIFRA].” 7 U.S.C. § 136a(f)(2).

20 99. However, FIFRA further provides that “In no event shall registration of an article be  
21 construed as a defense for the commission of any offense under [FIFRA].”

22 7 U.S.C. § 136a(f)(2).

23  
24 100. FIFRA further provides that “...it shall be unlawful for any person in any State to  
25 distribute or sell to any person... any pesticide which is... misbranded.”

26 7 U.S.C. § 136j(a)(1)(E).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

101. A pesticide is misbranded under FIFRA if, among other things:

- a. its labeling bears any statement, design, or graphic representation relative thereto or to its ingredients which is false or misleading in any particular, 7 U.S.C. § 136(q)(1)(A);
- b. the labeling accompanying it does not contain directions for use which are necessary for effecting the purpose for which the product is intended and if complied with, together with any requirements imposed under section 136a(d) of this title, are adequate to protect health and the environment, 7 U.S.C. § 136(q)(1)(F); or
- c. the label does not contain a warning or caution statement which may be necessary and if complied with, together with any requirements imposed under section 136a(d) of this title, is adequate to protect health and the environment,” 7 U.S.C. § 136(q)(1)(G).

102. Plaintiff do not seek in this action to impose on Defendants any labeling or packaging requirement in addition to or different from those required under FIFRA; accordingly, any allegation in this complaint that a Defendants breached a duty to provide adequate directions for the use of paraquat or warnings about paraquat, breached a duty to provide adequate packaging for paraquat, or concealed, suppressed, or omitted to disclose any material fact about paraquat or engaged in any unfair or deceptive practice regarding paraquat, is intended and should be construed to be consistent with that alleged breach, concealment, suppression, or omission, or unfair or deceptive practice, having rendered the paraquat “misbranded” under FIFRA.

103. Plaintiff brings claims and seek relief in this action only under state law. Plaintiff do not bring any claims or seek any relief in this action under FIFRA.

PANISH SHEA & BOYLE LLP  
11111 Santa Monica Boulevard, Suite 700  
Los Angeles, California 90025  
310.477.1700 phone • 310.477.1699 fax

1 **VII. Allegations common to specific causes of action<sup>5</sup>**

2 **A. Strict product liability – design defect**

3 104. At all relevant times, Defendants and those with whom they were acting in concert  
4 were engaged in business of designing, manufacturing, and selling paraquat within the U.S.

5 105. At all relevant times, Defendants and those with whom they were acting in concert  
6 intended and expected that Defendants’ paraquat products<sup>6</sup> would be sold and used in the States of  
7 Oregon.

8 106. Defendants and those with whom they were acting in concert developed, registered,  
9 manufactured, distributed, and sold paraquat for use in formulating Defendants’ paraquat products,  
10 and developed, registered, formulated and distributed Defendants’ paraquat products for sale and use  
11 in the U.S., including Oregon.

12 107. Upon information and belief, for many years, Plaintiff used Defendants’ paraquat  
13 products in Oregon and repeatedly and regularly for hours at a time, resulting in the repeated, regular,  
14 and prolonged exposure of Plaintiff to paraquat.

15 108. At all relevant times, Defendants’ paraquat products were in a defective condition that  
16 made them unreasonably dangerous when used in a manner that was intended or directed by or  
17  
18  
19  
20

21 \_\_\_\_\_  
22 <sup>5</sup> When used in an allegation in section VII or VIII of this Complaint, where the name of the party is not specified: (1)  
23 “Defendant” refers to the Defendants or Defendants from whom relief is sought in the Count in which the allegation  
24 appears or is incorporated and/or the predecessors of that Defendants or those Defendants; and (2) “Plaintiff” refers: (a)

25 to the Plaintiff seeking relief in the Count in which the allegation appears or is incorporated, where the Count seeks  
26 damages for personal injuries; or (b) to the spouses of the Plaintiff seeking relief in the Count in which the allegation  
27 appears or is incorporated, where the Count seeks damages for loss of society or consortium.  
28 <sup>6</sup> When used in an allegation in section VII or VIII of this Complaint, “Defendants’ paraquat products”: (1) refers to ICI □  
CHEVRON paraquat products and/or ICI □ SYNGENTA paraquat products when the allegation appears or is incorporated  
in a Count directed to SCPLLC and SAG; refers only to ICI □ CHEVRON paraquat products when the allegation appears  
or is incorporated in a Count directed to CUSA.

1 reasonably foreseeable to, and was known to or foreseen by, Defendants and those with whom they  
2 were acting in concert, in that:

- 3 a. they were designed, manufactured, formulated, and packaged such that when so used,  
4 paraquat was likely to be inhaled, ingested, and absorbed into the bodies of persons  
5 who used them, were nearby while they were being used, or entered fields or orchards  
6 where they had been sprayed or areas near where they had been sprayed; and
- 7 b. when inhaled, ingested, or absorbed into the bodies of persons who used them, were  
8 nearby while they were being used, or entered fields or orchards where they had been  
9 sprayed or areas near where they had been sprayed, paraquat was likely to cause or  
10 contribute to cause latent, permanent, and cumulative neurological damage, and  
11 repeated exposures were likely to cause or contribute to cause clinically significant  
12 neurodegenerative disease, including Parkinson's disease, to develop over time and  
13 manifest long after exposure.

14 109. At all relevant times, this defective condition in Defendants' paraquat products existed  
15 when they left the control of Defendants and those with whom they were acting in concert and were  
16 placed into the stream of commerce.

17 110. At all relevant times, Defendants and those with whom they were acting in concert  
18 knew or foresaw that this defective condition of Defendants' paraquat products would create a  
19 substantial risk of harm to persons who used them, were nearby while they were being used, or  
20 entered fields or orchards where they had been sprayed or areas near where they had been sprayed,  
21 but in conscious disregard for the safety of others, including Plaintiff, continued to place them into  
22 the stream of commerce.

23 111. As a result of this defective condition, Defendants' paraquat products either failed to  
24 perform in the manner reasonably to be expected in light of their nature and intended function, or the  
25 magnitude of the dangers outweighed their utility.

26 112. At all relevant times, Defendants' paraquat products were used in a manner that was  
27 intended or directed by or reasonably foreseeable to, and was known to or foreseen by, Defendants  
28 and those with whom they were acting in concert.



1 113. At all relevant times, Defendants concealed the defective condition of their product  
2 from Plaintiff thus preventing Plaintiff from discovering the causal link between their injury and  
3 paraquat.

4 **B. Strict product liability – Failure to warn**

5 114. At all relevant times, Defendants and those with whom they were acting in concert  
6 were engaged in the U.S. paraquat business.

7 115. At all relevant times, Defendants and those with whom they were acting in concert  
8 intended and expected that Defendants’ paraquat products would be sold and used in the State of  
9 Oregon.

10 116. Defendants and those with whom they were acting in concert developed, registered,  
11 manufactured, distributed, and sold paraquat for use in formulating Defendants’ paraquat products,  
12 and developed, registered, formulated and distributed Defendants’ paraquat products for sale and use  
13 in the U.S., including Oregon.

14 117. Upon information and belief, for many years, Plaintiff used Defendants’ paraquat  
15 products in Oregon repeatedly and regularly for hours at a time, resulting in the repeated, regular,  
16 and prolonged exposure of Plaintiff to paraquat.

17 118. At all relevant times, Defendants and those with whom they were acting in concert  
18 should have known in the exercise of ordinary care, and did know, that when used in a manner that  
19 was intended or directed by or reasonably foreseeable to, and was known to or foreseen by,  
20 Defendants and those with whom it was acting in concert:

- 21  
22  
23  
24 a. Defendants’ paraquat products were designed, manufactured, formulated, and  
25 packaged such that when so used, paraquat was likely to be inhaled, ingested, and  
26 absorbed into the bodies of persons who used them, were nearby while they were  
27 being used, or entered fields or orchards where they had been sprayed or areas near  
28 where they had been sprayed; and

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

- b. when inhaled, ingested, or absorbed into the bodies of persons who used them, were nearby while they were being used, or entered fields or orchards where they had been sprayed or areas near where they had been sprayed, paraquat was likely to cause or contribute to cause latent, cumulative, and permanent neurological damage, and repeated exposures were likely to cause or contribute to cause clinically significant neurodegenerative disease, including Parkinson’s disease, to develop over time and manifest long after exposure.

119. At all relevant times, Defendants’ paraquat products were in a defective condition that made them unreasonably dangerous when used in a manner that was intended or directed by or reasonably foreseeable to, and was known to or foreseen by, Defendants and those with whom they were acting in concert, in that:

- a. they were not accompanied by directions for use that would have made paraquat unlikely to be inhaled, ingested, and absorbed into the bodies of persons who used them, were nearby while they were being used, or entered fields or orchards where they had been sprayed or areas near where they had been sprayed; and
- b. they were not accompanied by a warning that when inhaled, ingested, or absorbed into the bodies of persons who used them, were nearby while they were being used, or entered fields or orchards where they had been sprayed or areas near where they had been sprayed, paraquat was likely to cause or contribute to cause latent, cumulative, and permanent neurological damage, and that repeated exposures were likely to cause or contribute to cause clinically significant neurodegenerative disease, including Parkinson’s disease, to develop over time and manifest long after exposure.

120. At all relevant times, this defective condition in Defendants’ paraquat products existed when they left the control of Defendants and those with whom they were acting in concert and were placed into the stream of commerce.

121. At all relevant times, Defendants and those with whom it was acting in concert knew this defective condition of Defendants’ paraquat products created a substantial risk of harm to persons who used them, were nearby while they were being used, or entered fields or orchards where they had been sprayed or areas near where they had been sprayed, but in conscious disregard for the safety of others, including Plaintiff, continued to place them into the stream of commerce.

1 122. As a result of this defective condition, Defendants' paraquat products either failed to  
2 perform in the manner reasonably to be expected in light of their nature and intended function, or the  
3 magnitude of the dangers outweighed their utility.

4 123. At all relevant times, Defendants' paraquat products were used in a manner that was  
5 intended or directed by or reasonably foreseeable to, and was known to or foreseen by, Defendants  
6 and those with whom they were acting in concert.

7 124. At all relevant times, Defendants concealed the defective condition of their product  
8 from Plaintiff thus preventing Plaintiff from discovering the causal link between their injury and  
9 paraquat.  
10

11 **C. Negligence**

12 125. At all relevant times, Defendants and those with whom they were acting inconcert  
13 were engaged in the U.S. paraquat business.

14 126. At all relevant times, Defendants and those with whom they were acting in concert  
15 intended and expected that Defendants' paraquat products would be sold and used in the State of  
16 Oregon.  
17

18 127. Defendants and those with whom they were acting in concert developed, registered,  
19 manufactured, distributed, and sold paraquat for use in formulating Defendants' paraquat products,  
20 and developed, registered, formulated and distributed Defendants' paraquat products for sale and use  
21 in the U.S., including Oregon.

22 128. Upon information and belief, for many years, Plaintiff used Defendants' paraquat  
23 products in Oregon repeatedly and regularly for hours at a time, resulting in the repeated, regular,  
24 and prolonged exposure of Plaintiff to paraquat.  
25  
26  
27

1 129. At all relevant times, in designing, manufacturing, and distributing paraquat for use  
2 in formulating paraquat products and in designing, formulating, packaging, labeling, and distributing  
3 paraquat products, Defendants and those with whom they were acting in concert owed a duty to  
4 exercise ordinary care for the health and safety of persons, including Plaintiff, whom it was  
5 reasonably foreseeable could be exposed to paraquat in such products.

6 130. When Defendants and those with whom they were acting in concert designed,  
7 manufactured, and distributed paraquat for use in formulating Defendants' paraquat products and  
8 designed, formulated, packaged, labeled, and distributed Defendants' paraquat products, it was  
9 reasonably foreseeable and in the exercise of ordinary care Defendants should have known, and  
10 Defendants did know, that when Defendants' paraquat products were used in a manner that was  
11 intended or directed by or reasonably foreseeable to, and was known to or foreseen by, Defendants  
12 and those with whom they were acting in concert:

- 13
- 14 a. they were designed, manufactured, formulated, and packaged such that paraquat was  
15 likely to be inhaled, ingested, and absorbed into the bodies of persons who used them,  
16 were nearby while they were being used, or entered fields or orchards where they had  
17 been sprayed or areas near where they had been sprayed; and
  - 18 b. when inhaled, ingested, or absorbed into the bodies of persons whoused them, were  
19 nearby while they were being used, or entered fields or orchards where they had been  
20 sprayed or areas near where they had been sprayed, paraquat was likely to cause or  
21 contribute to cause latent, cumulative, and permanent neurological damage, and  
repeated exposures were likely to cause or contribute to cause clinically significant  
neurodegenerative disease, including Parkinson's disease, to develop over time and  
manifest long after exposure.

22 131. In breach of their duty to Plaintiff, Defendants and those with whom they were acting  
23 in concert negligently, and in conscious disregard for the safety of others:

- 24 a. failed to design, manufacture, formulate, and package Defendants' paraquat products  
25 to make paraquat unlikely to be inhaled, ingested, and absorbed into the bodies of  
26 persons who used them, were nearby while they were being used, or entered fields or  
orchards where they had been sprayed or areas near where they had been sprayed;

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

- b. designed and manufactured paraquat and designed and formulated Defendants’ paraquat products such that when inhaled, ingested, or absorbed into the bodies of persons who used Defendants’ paraquat products, were nearby while they were being used, or entered fields or orchards where they had been sprayed or areas near where they had been sprayed, paraquat was likely to cause or contribute to cause latent, cumulative, and permanent neurological damage, and repeated exposures were likely to cause or contribute to cause clinically significant neurodegenerative disease, including Parkinson’s disease, to develop over time and manifest long after exposure;
- c. failed to perform adequate testing to determine the extent to which exposure to paraquat was likely to occur through inhalation, ingestion, and absorption into the bodies of persons who used Defendants’ paraquat products, were nearby while they were being used, or entered fields or orchards where they had been sprayed or areas near where they had been sprayed;
- d. failed to perform adequate testing to determine the extent to which spray drift from Defendants’ paraquat products was likely to occur, including their propensity to drift, the distance they were likely to drift, and the extent to which paraquat spray droplets were likely to enter the bodies of persons spraying Defendants’ paraquat products or nearby during or after spraying;
- e. failed to perform adequate testing to determine the extent to which paraquat, when inhaled, ingested, or absorbed into the bodies of persons who used Defendants’ paraquat products, were nearby while they were being used, or entered fields or orchards where they had been sprayed or areas near where they had been sprayed, was likely to cause or contribute to cause latent, cumulative, and permanent neurological damage, and the extent to which repeated exposures were likely to cause or contribute to cause clinically significant neurodegenerative disease, including Parkinson’s disease, to develop over time and manifest long after exposure;
- f. failed to perform adequate testing to determine the extent to which paraquat, when formulated or mixed with surfactants or other pesticides or used along with other pesticides, and inhaled, ingested, or absorbed into the bodies of persons who used Defendants’ paraquat products, were nearby while they were being used, or entered fields or orchards where they had been sprayed or areas near where they had been sprayed, was likely to cause or contribute to cause latent, cumulative, and permanent neurological damage, and the extent to which repeated exposures were likely to cause or contribute to cause clinically significant neurodegenerative disease, including Parkinson’s disease, to develop over time and manifest long after exposure;
- g. failed to direct that Defendants’ paraquat products be used in a manner that would have made it unlikely for paraquat to have been inhaled, ingested, and absorbed into the bodies of persons who used them, were nearby while they were being used, or entered fields or orchards where they had been sprayed or areas near where they had been sprayed; and

1 h. failed to warn that when inhaled, ingested, or absorbed into the bodies of persons who  
2 used Defendants' paraquat products, were nearby while they were being used, or  
3 entered fields or orchards where they had been sprayed or areas near where they had  
4 been sprayed, paraquat was likely to cause or contribute to cause latent, cumulative,  
5 and permanent neurological damage, and repeated exposures were likely to cause or  
6 contribute to cause clinically significant neurodegenerative disease, including  
7 Parkinson's disease, to develop over time and manifest long after exposure.

8 132. At all relevant times, Defendants' paraquat products were used in a manner that was  
9 intended or directed by or reasonably foreseeable to, and was known to or foreseen by, Defendants  
10 and those with whom they were acting in concert.

11 133. At all relevant times, Defendants concealed the dangers of their product as listed  
12 above from Plaintiff thus preventing Plaintiff from discovering the causal link between their injury  
13 and paraquat.

14 **D. Public nuisance**

15 134. At all relevant times, Defendants and those with whom it was acting in concert were  
16 engaged in the U.S. paraquat business.

17 135. At all relevant times, Defendants and those with whom it was acting in concert  
18 intended and expected that Defendants' paraquat products would be sold and used in the State of  
19 Oregon.

20 136. Defendants and those with whom it was acting in concert developed, registered,  
21 manufactured, distributed, and sold paraquat for use in formulating Defendants' paraquat products,  
22 and developed, registered, formulated and distributed Defendants' paraquat products for sale and use  
23 in the U.S., including Oregon.

24 137. Upon information and belief, for many years, Plaintiff used Defendants' paraquat  
25 products in Oregon repeatedly and regularly for hours at a time, resulting in the repeated, regular,  
26 and prolonged exposure of Plaintiff to paraquat.

1 138. At all relevant times, Defendants and those with whom they were acting in concert  
2 owed a duty to the public, including Plaintiff and other persons whom they could reasonably foresee  
3 were likely to use Defendants' paraquat products or otherwise be in or near places where they were  
4 being or recently had been used within the State of Oregon, to provide and maintain a healthful  
5 environment and uphold the public's and Plaintiff's right to a healthful environment in connection  
6 with the design, manufacture, and distribution of paraquat for use in formulating Defendants'  
7 paraquat products, and the design, formulation and distribution of Defendants' paraquat products,  
8 that Defendants intended and expected to be used in the State of Oregon.  
9

10 139. When Defendants and those with whom they were acting in concert designed,  
11 manufactured, and distributed paraquat for use in formulating Defendants' paraquat products and  
12 designed, formulated, packaged, labeled, and distributed Defendants' paraquat products, it was  
13 reasonably foreseeable and in the exercise of ordinary care Defendants should have known, and  
14 Defendants did know, that when Defendants' paraquat products were used in a manner that was  
15 intended or directed by or reasonably foreseeable to, and was known to or foreseen by, Defendants  
16 and those with whom it was acting in concert:  
17

- 18 a. they were designed, manufactured, formulated, and packaged such that paraquat was  
19 likely to be inhaled, ingested, and absorbed into the bodies of persons who used them,  
20 were nearby while they were being used, or entered fields or orchards where they had  
21 been sprayed or areas near where they had been sprayed; and  
22  
23 b. when inhaled, ingested, or absorbed into the bodies of persons who used them, were  
24 nearby while they were being used, or entered fields or orchards where they had been  
25 sprayed or areas near where they had been sprayed, paraquat was likely to cause or  
26 contribute to cause latent, cumulative, and permanent neurological damage, and  
27 repeated exposures were likely to cause or contribute to cause clinically significant  
28 neurodegenerative disease, including Parkinson's disease, to develop over time and  
manifest long after exposure.

1 140. In breach of their duty to members of the public, including Plaintiff, Defendants and  
2 those with whom it was acting in concert negligently, and in conscious disregard for the safety of  
3 others:

- 4 a. failed to design, manufacture, formulate, and package Defendants' paraquat products  
5 to make paraquat unlikely to be inhaled, ingested, and absorbed into the bodies of  
6 persons who used them, were nearby while they were being used, or entered fields or  
7 orchards where they had been sprayed or areas near where they had been sprayed;
- 8 b. designed and manufactured paraquat and designed and formulated Defendants'  
9 paraquat products such that when inhaled, ingested, or absorbed into the bodies of  
10 persons who used Defendants' paraquat products, were nearby while they were being  
11 used, or entered fields or orchards where they had been sprayed or areas near where  
12 they had been sprayed, paraquat was likely to cause or contribute to cause latent,  
13 cumulative, and permanent neurological damage, and repeated exposures were likely  
14 to cause or contribute to cause clinically significant neurodegenerative disease,  
15 including Parkinson's disease, to develop over time and manifest long after exposure;
- 16 c. failed to perform adequate testing to determine the extent to which exposure to  
17 paraquat was likely to occur through inhalation, ingestion, and absorption into the  
18 bodies of persons who used Defendants' paraquat products, were nearby while they  
19 were being used, or entered fields or orchards where they had been sprayed or areas  
20 near where they had been sprayed;
- 21 d. failed to perform adequate testing to determine the extent to which spray drift from  
22 Defendants' paraquat products was likely to occur, including their propensity to drift,  
23 the distance they were likely to drift, and the extent to which paraquat spray droplets  
24 were likely to enter the bodies of persons spraying Defendants' paraquat products or  
25 nearby during or after spraying;
- 26 e. failed to perform adequate testing to determine the extent to which paraquat, when  
27 inhaled, ingested, or absorbed into the bodies of persons who used Defendants'  
28 paraquat products, were nearby while they were being used, or entered fields or  
orchards where they had been sprayed or areas near where they had been sprayed, was  
likely to cause or contribute to cause latent, cumulative, and permanent neurological  
damage, and the extent to which repeated exposures were likely to cause or contribute  
to cause clinically significant neurodegenerative disease, including Parkinson's  
disease, to develop over time and manifest long after exposure;
- f. failed to perform adequate testing to determine the extent to which paraquat, when  
formulated or mixed with surfactants or other pesticides or used along with other  
pesticides, and inhaled, ingested, or absorbed into the bodies of persons who used  
Defendants' paraquat products, were nearby while they were being used, or entered  
fields or orchards where they had been sprayed or areas near where they had been



1 sprayed, was likely to cause or contribute to cause latent, cumulative, and permanent  
2 neurological damage, and the extent to which repeated exposures were likely to cause  
3 or contribute to cause clinically significant neurodegenerative disease, including  
4 Parkinson’s disease, to develop over time and manifest long after exposure;

5 g. failed to direct that Defendants’ paraquat products be used in a manner that would  
6 have made it unlikely for paraquat to have been inhaled, ingested, and absorbed into  
7 the bodies of persons who used them, were nearby while they were being used, or  
8 entered fields or orchards where they had been sprayed or areas near where they had  
9 been sprayed; and

10 h. failed to warn that when inhaled, ingested, or absorbed into the bodies of persons who  
11 used Defendants’ paraquat products, were nearby while they were being used, or  
12 entered fields or orchards where they had been sprayed or areas near where they had  
13 been sprayed, paraquat was likely to cause or contribute to cause latent, cumulative,  
14 and permanent neurological damage, and repeated exposures were likely to cause or  
15 contribute to cause clinically significant neurodegenerative disease, including  
16 Parkinson’s disease, to develop over time and manifest long after exposure.

17 141. At all relevant times, Defendants’ paraquat products were used in a manner that was  
18 intended or directed by or reasonably foreseeable to, and was known to and foreseen by, Defendants  
19 and those with whom it was acting in concert.

20 **E. The Oregon Unlawful Trade Practices Act, Or. Rev. Stat. §§ 646.605, et seq.**

21 142. At all relevant times, Defendants and those with whom they were acting in concert  
22 were engaged in the U.S. paraquat business.

23 143. At all relevant times, Defendants and those with whom they were acting in concert  
24 intended and expected that Defendants’ paraquat products would be sold and used in the State of  
25 Oregon.

26 144. Defendants and those with whom they were acting in concert developed, registered,  
27 manufactured, distributed, and sold paraquat for use in formulating Defendants’ paraquat products,  
28 and developed, registered, formulated and distributed Defendants’ paraquat products for sale and use  
in the U.S., including Oregon.

1 145. Upon information and belief, Plaintiff Lloyd Parsons and/or his employers purchased  
2 Defendants' paraquat products in Oregon for the purpose of controlling weeds and not for resale, and  
3 for many years, Plaintiff used these products in Oregon repeatedly and regularly for hours at a time,  
4 resulting in the repeated, regular, and prolonged exposure of Plaintiff to paraquat.

5 146. At all relevant times and upon information and belief, Plaintiff, Defendant, and others  
6 with whom Defendants acted in concert, were persons within the meaning of Or. Rev. Stat. §  
7 646.605(4).  
8

9 147. At all relevant times, Plaintiff Lloyd Parsons was a consumer.

10 148. The Oregon Unlawful Trade Practices Act, Or. Rev. Stat. § 646.08 (e); (g), provides  
11 in pertinent part:

12 A person engages in an unlawful practice if in the course of the person's business,  
13 vocation or occupation the person does any of the following: [...] Represents that real  
14 estate, goods or services have sponsorship, approval, characteristics, ingredients, uses,  
15 benefits, quantities or qualities that the real estate, goods or services do not have or  
16 that a person has a sponsorship, approval, status, qualification, affiliation, or  
17 connection that the person does not have [...] Represents that real estate, goods or  
18 services are of a particular standard, quality, or grade, or that real estate or goods are  
19 of a particular style or model, if the real estate, goods or services are of another.

20 149. At all relevant times, Defendants and those with whom they were acting in concert  
21 had both constructive and actual knowledge that when Defendants' paraquat products were used in  
22 a manner that was intended or directed by or reasonably foreseeable to, and was known to or foreseen  
23 by, Defendants and those with whom they were acting in concert:

- 24 a. they were designed, manufactured, formulated, and packaged such that paraquat was  
25 likely to be inhaled, ingested, and absorbed into the bodies of persons who used them,  
26 were nearby while they were being used, or entered fields or orchards where they had  
27 been sprayed or areas near where they had been sprayed; and  
28 b. when inhaled, ingested, or absorbed into the bodies of persons who used them, were  
nearby while they were being used, or entered fields or orchards where they had been  
sprayed or areas near where they had been sprayed, paraquat was likely to cause or  
contribute to cause latent, cumulative, and permanent neurological damage, and

1 repeated exposures were likely to cause or contribute to cause clinically significant  
2 neurodegenerative disease, including Parkinson's disease, to develop over time and  
manifest long after exposure.

3 150. At all relevant times, Defendants and those with whom they were acting in concert  
4 had both constructive and actual knowledge that:

- 5 a. adequate testing had not been performed to determine the extent to which exposure to  
6 paraquat was likely to occur through inhalation, ingestion, and absorption into the  
7 bodies of persons who used Defendants' paraquat products, were nearby while they  
8 were being used, or entered fields or orchards where they had been sprayed or areas  
near where there had been sprayed;
- 9 b. adequate testing had not been performed to determine the extent to which spray drift  
10 was likely to occur when Defendants' paraquat products were used, including their  
11 propensity to drift, the distance they were likely to drift, and the extent to which  
paraquat spray droplets were likely to enter the bodies of persons spraying or others  
nearby during or after spraying;
- 12 c. adequate testing had not been performed to determine the extent to which paraquat,  
13 when inhaled, ingested, or absorbed into the bodies of persons who used Defendants'  
14 paraquat products, were nearby while they were being used, or entered fields or  
15 orchards where they had been sprayed or areas near where they had been sprayed,  
16 were likely to cause or contribute to cause latent, cumulative, and permanent  
neurological damage, and the extent to which repeated exposures were likely to cause  
or contribute to cause clinically significant neurodegenerative disease, including  
Parkinson's disease, to develop over time and manifest long after exposure; and
- 17 d. adequate testing had not been performed to determine the extent to which paraquat,  
18 when formulated or mixed with surfactants or other pesticides or used along with  
19 other pesticides, and inhaled, ingested, or absorbed into the bodies of persons who  
20 used Defendants' paraquat products, were nearby while they were being used, or  
21 entered fields or orchards where they had been sprayed or areas near where there had  
22 been sprayed, was likely to cause or contribute to cause latent, cumulative, and  
permanent neurological damage, and the extent to which repeated exposures were  
likely to cause or contribute to cause clinically significant neurodegenerative disease,  
including Parkinson's disease, to develop over time and manifest long after exposure.

23 151. From the first date on which Defendants and those with whom they were acting in  
24 concert placed Defendants' paraquat products into the stream of commerce for use in the State of  
25 Oregon through the last date on which Plaintiff was exposed to Defendants' paraquat products,  
26 Defendants and those with whom they were acting in concert engaged in unfair or deceptive acts or  
27

1 practices, including but not limited to deception, fraud, false pretense, false promise,  
2 misrepresentation or the concealment, suppression, or omission of material facts, in designing,  
3 manufacturing, and distributing paraquat for use in formulating Defendants' paraquat products for  
4 distribution for sale and use in the State of Oregon and in designing, formulating, and distributing  
5 Defendants' paraquat products for sale and use in the State of Oregon, in that they:

- 6
- 7 a. concealed, suppressed, or omitted to disclose that Defendants' paraquat products were  
8 designed, manufactured, formulated, and packaged such that paraquat was likely to  
9 be inhaled, ingested, and absorbed into the bodies of persons who used them, were  
10 nearby while they were being used, or entered fields or orchards where they had been  
11 sprayed or areas near where they had been sprayed;
- 12 b. concealed, suppressed, or omitted to disclose that when inhaled, ingested, or absorbed  
13 into the bodies of persons who used Defendants' paraquat products, were nearby while  
14 they were being used, or entered fields or orchards where they had been sprayed  
15 or areas near where they had been sprayed, paraquat was likely to cause or contribute  
16 to cause latent, cumulative, and permanent neurological damage, and repeated  
17 exposures were likely to cause or contribute to cause clinically significant  
18 neurodegenerative disease, including Parkinson's disease, to develop over time and  
19 manifest long after exposure;
- 20 c. concealed, suppressed, or omitted to disclose that adequate testing had not been  
21 performed to determine the extent to which exposure to paraquat was likely to occur  
22 through inhalation, ingestion, and absorption into the bodies of persons who used  
23 Defendants' paraquat products, were nearby while they were being used, or entered  
24 fields or orchards where they had been sprayed or areas near where they had been  
25 sprayed;
- 26 d. concealed, suppressed, or omitted to disclose that adequate testing had not been  
27 performed to determine the extent to which spray drift was likely to occur when  
28 Defendants' paraquat products were used, including their propensity to drift, the  
distance they were likely to drift, and the extent to which paraquat spray droplets were  
likely to enter the bodies of persons spraying or others nearby during or after spraying;
- 29 e. concealed, suppressed, or omitted to disclose that adequate testing had not been  
performed to determine the extent to which paraquat, when inhaled, ingested, or  
absorbed into the bodies of persons who used Defendants' paraquat products, were  
nearby while they were being used, or entered fields or orchards where they had been  
sprayed or areas near where they had been sprayed, was likely to cause or contribute  
to cause latent, cumulative, and permanent neurological damage, and the extent to  
which repeated exposures were likely to cause or contribute to cause clinically  
significant neurodegenerative disease, including Parkinson's disease, to develop over

1 time and manifest long after exposure; and

- 2 f. concealed, suppressed, or omitted to disclose that adequate testing had not been  
3 performed to determine the extent to which paraquat, when formulated or mixed with  
4 surfactants or other pesticides or used along with other pesticides, and inhaled,  
5 ingested, or absorbed into the bodies of persons who used Defendants' paraquat  
6 products, were nearby while they were being used, or entered fields or orchards where  
7 they had been sprayed or areas near where they had been sprayed, was likely to cause  
8 or contribute to cause latent, cumulative, and permanent neurological damage, and the  
9 extent to which repeated exposures were likely to cause or contribute to cause  
10 clinically significant neurodegenerative disease, including Parkinson's disease, to  
11 develop over time and manifest long after exposure.

12 152. These acts and practices of Defendants and those with whom they were acting in  
13 concert in designing, manufacturing, and distributing paraquat for use in formulating Defendants'  
14 paraquat products for distribution for sale and use in the State of Oregon and in designing,  
15 formulating, and distributing Defendants' paraquat products for sale and use in the State of Oregon  
16 were unfair because they offended public policy, were immoral, unethical, oppressive, and  
17 unscrupulous, and caused substantial injury to consumers.

18 153. These acts and practices of Defendants and those with whom they were acting in  
19 concert in designing, manufacturing, and distributing paraquat for use in formulating Defendants'  
20 paraquat products for distribution for sale and use in the State of Oregon and in designing,  
21 formulating, and distributing Defendants' paraquat products for sale and use in the State of Oregon  
22 offended the clearly stated public policy of the State of Oregon, as expressed in Cal. Const. Art. I, §  
23 I, that "[a]ll people are by nature free and independent and have inalienable rights. Among these are  
24 enjoying and defending life and liberty, acquiring, possessing, and protecting property, and pursuing  
25 and obtaining safety, happiness, and privacy."

26 154. These acts and practices of Defendants and those with whom they were acting in  
27 concert in designing, manufacturing, and distributing paraquat for use in formulating Defendants'  
28 paraquat products for distribution for sale and use in the State of Oregon and in designing,

1 formulating, and distributing Defendants’ paraquat products for sale and use in the State of Oregon  
2 offended the clearly stated public policy of the State of Oregon, as expressed in Or. Rev. Stat. § 468,  
3 that:

- 4 a. In the interest of the public peace, health and safety, it is the policy of the State  
5 of Oregon to assist in the prevention, control and reduction of air, water and  
6 noise pollution and solid waste, hazardous wastes and used oil in this state ...
- 7 b. It the policy of this state to support the maintenance, enhancement and  
8 restoration of ecosystem services throughout Oregon, focusing on the  
9 protection of land, water, air, soil and native flora and fauna.

10 155. The public policy of the State of Oregon is further expressed in Article XV of the  
Oregon Constitution, which provides:

11 The people of the State of Oregon also find that renewal of the Parks and Natural  
12 Resources Fund will support voluntary efforts to: (1) Protect and restore water quality,  
13 watersheds and habitats for native fish and wildlife that provide a healthy environment  
for current and future generations of Oregonians...

14 156. These acts and practices of Defendants and those with whom they were acting in  
15 concert in designing, manufacturing, and distributing paraquat for use in formulating Defendants’  
16 paraquat products for distribution for sale and use in the State of Oregon and in designing,  
17 formulating, and distributing Defendants’ paraquat products for sale and use in the State of Oregon  
18 were immoral and unethical, as they served only to benefit Defendants and those with whom they  
19 were acting in concert at the expense of the heath of purchasers and users of Defendants’ paraquat  
20 products and the public.

21 157. These acts and practices of Defendants and those with whom they were acting in  
22 concert in designing, manufacturing, and distributing paraquat for use in formulating Defendants’  
23 paraquat products for distribution for sale and use in the State of Oregon and in designing,  
24 formulating, and distributing Defendants’ paraquat products for sale and use in the State of Oregon  
25

1 were likely to cause substantial injury to purchasers and users of paraquat and the public by exposing  
2 them to unnecessary risks to their health.

3 158. These acts and practices of Defendants and those with whom they were acting in  
4 concert in designing, manufacturing, and distributing paraquat for use in formulating Defendants'  
5 paraquat products for distribution for sale and use in the State of Oregon and in designing,  
6 formulating, and distributing Defendants' paraquat products for sale and use in the State of Oregon  
7 were likely to cause, and did cause, substantial injury to purchasers and users of paraquat and the  
8 public in that but for these acts and practices, Defendants' paraquat products would not have been  
9 purchased for use in Oregon and persons who used them, were nearby while they was being used, or  
10 entered fields or orchards where they had been sprayed or areas near where it they been sprayed,  
11 would not have been injured by exposure to paraquat.

12  
13 159. Defendants and those with whom they were acting in concert in designing,  
14 manufacturing, and distributing paraquat for use in formulating Defendants' paraquat products for  
15 distribution for sale and use in the State of Oregon and in designing, formulating, and distributing  
16 Defendants' paraquat products for sale and use in the State of Oregon committed these acts and  
17 engaged in these practices in conscious disregard of the safety of others, including Plaintiff Lloyd  
18 Parsons.

19  
20 160. The injuries caused by these acts and practices of Defendants and those with whom  
21 they were acting in concert in designing, manufacturing, and distributing paraquat for use in  
22 formulating Defendants' paraquat products for distribution for sale and use in the State of Oregon  
23 and in designing, formulating, and distributing Defendants' paraquat products for sale and use in the  
24 State of Oregon—namely, purchasers' monetary losses and the injuries and damages (including  
25 monetary losses) to persons who used them, were nearby while they were being used, or entered  
26

1 fields or orchards where they had been sprayed or areas near where they had been sprayed, including  
2 Plaintiff Lloyd Parsons—are not outweighed by any countervailing benefit to consumers or  
3 competition.

4 161. The injuries caused by these acts and practices of Defendants and those with whom  
5 they were acting in concert in designing, manufacturing, and distributing paraquat for use in  
6 formulating Defendants’ paraquat products for distribution for sale and use in the State of Oregon  
7 and in designing, formulating, and distributing Defendants’ paraquat products for sale and use in the  
8 State of Oregon—namely, purchasers’ monetary losses and the injuries and damages (including  
9 monetary losses) to persons who used them, were nearby while they were being used, or entered  
10 fields or orchards where they had been sprayed or areas near where they had been sprayed, including  
11 Plaintiff—were not reasonably avoidable; because Defendants and those with whom they were acting  
12 in concert had and failed to disclose material non-public information, consumers had no reason to  
13 anticipate the impending harm and thus avoid their injuries.  
14

15 162. Defendants and those with whom they were acting in concert intended that purchasers  
16 of Defendants’ paraquat products, including Plaintiff Lloyd Parsons, purchase them in reliance on  
17 these unfair and deceptive acts and practices.  
18

19 163. The facts that Defendants and those with whom they were acting in concert concealed,  
20 suppressed, or omitted to disclose were material to the decisions to purchase Defendants’ paraquat  
21 products, and would not have been purchased had these facts been disclosed.  
22

23 164. These unfair and deceptive acts and practices of Defendants and those with whom  
24 they were acting in concert occurred in connection with their conduct of trade and commerce in the  
25 State of Oregon.  
26



1 165. These unfair and deceptive acts and practices of Defendants and those with whom  
2 they were acting in concert violated the Oregon Unlawful Trade Practices Act, Or. Rev. Stat. §§  
3 646.605, *et seq.*

4 166. Defendants and those with whom they were acting in concert committed these unfair  
5 and deceptive practices knowing they created a substantial risk of harm to Plaintiff Lloyd Parsons  
6 and others who purchased and used Defendants' paraquat products in Oregon.

7  
8 **F. California Consumer Legal Remedies Act, Cal. Civ. § 1750, *et seq.***

9 167. At all relevant times, Defendants and those with whom they were acting in concert  
10 were engaged in the U.S. paraquat business.

11 168. At all relevant times, Defendants and those with whom they were acting in concert  
12 intended and expected that Defendants' paraquat products would be sold from in the State of  
13 California and used in other states such as Oregon.

14 169. Defendants and those with whom they were acting in concert developed, registered,  
15 manufactured, distributed, and sold paraquat for use in formulating Defendants' paraquat products,  
16 and developed, registered, formulated and distributed Defendants' paraquat products for sale in the  
17 U.S., including California and used in other states such as Oregon.

18 170. Upon information and belief, Plaintiff Lloyd Parsons's employers purchased  
19 Defendants' paraquat products in California for the purpose of controlling weeds and not for resale,  
20 and for many years, Plaintiff Lloyd Parsons used these products that developed, registered,  
21 manufactured, distributed, and sold from California in Oregon repeatedly and regularly for hours at  
22 a time, resulting in the repeated, regular, and prolonged exposure of Plaintiff Lloyd Parsons to  
23 paraquat.  
24  
25  
26  
27  
28

1 171. At all relevant times and upon information and belief, Plaintiff Lloyd Parsons,  
2 Defendant, and others with whom Defendant acted in concert, were persons within the meaning of  
3 Cal. Civ. Code § 1761(c).

4 172. At all relevant times, Plaintiff Lloyd Parsons was a consumer within the meaning of  
5 Cal. Civ. Code § 1761(d).

6 173. The California Consumer Legal Remedies Act, Cal. Civ. § 1770(a)(5); (7), provides  
7 in pertinent part:  
8

9 The following unfair methods of competition and unfair or deceptive acts or practices  
10 undertaken by any person in a transaction intended to result or that results in the sale  
11 or lease of goods or services to any consumer are unlawful: Representing that goods  
12 or services have sponsorship, approval, characteristics, ingredients, uses, benefits, or  
13 quantities that they do not have or that a person has a sponsorship, approval, status,  
14 affiliation, or connection that he or she does not have [...] Representing that goods or  
15 services are of a particular standard, quality, or grade, or that goods are of a particular  
16 style or model, if they are of another.

17 174. At all relevant times, Defendants and those with whom they were acting in concert  
18 had both constructive and actual knowledge that when Defendants' paraquat products were used in  
19 a manner that was intended or directed by or reasonably foreseeable to, and was known to or foreseen  
20 by, Defendants and those with whom they were acting in concert:

- 21 a. they were designed, manufactured, formulated, and packaged such that paraquat was  
22 likely to be inhaled, ingested, and absorbed into the bodies of persons who used them,  
23 were nearby while they were being used, or entered fields or orchards where they had  
24 been sprayed or areas near where they had been sprayed; and  
25 b. when inhaled, ingested, or absorbed into the bodies of persons who used them, were  
26 nearby while they were being used, or entered fields or orchards where they had been  
27 sprayed or areas near where they had been sprayed, paraquat was likely to cause or  
28 contribute to cause latent, cumulative, and permanent neurological damage, and  
repeated exposures were likely to cause or contribute to cause clinically significant  
neurodegenerative disease, including Parkinson's disease, to develop over time and  
manifest long after exposure.

1 175. At all relevant times, Defendants and those with whom they were acting in concert  
2 had both constructive and actual knowledge that:

- 3 a. adequate testing had not been performed to determine the extent to which exposure to  
4 paraquat was likely to occur through inhalation, ingestion, and absorption into the  
5 bodies of persons who used Defendants' paraquat products, were nearby while they  
6 were being used, or entered fields or orchards where they had been sprayed or areas  
7 near where there had been sprayed;
- 8 b. adequate testing had not been performed to determine the extent to which spray drift  
9 was likely to occur when Defendants' paraquat products were used, including their  
10 propensity to drift, the distance they were likely to drift, and the extent to which  
11 paraquat spray droplets were likely to enter the bodies of persons spraying or others  
12 nearby during or after spraying;
- 13 c. adequate testing had not been performed to determine the extent to which paraquat,  
14 when inhaled, ingested, or absorbed into the bodies of persons who used Defendants'  
15 paraquat products, were nearby while they were being used, or entered fields or  
16 orchards where they had been sprayed or areas near where they had been sprayed,  
17 were likely to cause or contribute to cause latent, cumulative, and permanent  
18 neurological damage, and the extent to which repeated exposures were likely to cause  
19 or contribute to cause clinically significant neurodegenerative disease, including  
20 Parkinson's disease, to develop over time and manifest long after exposure; and
- 21 d. adequate testing had not been performed to determine the extent to which paraquat,  
22 when formulated or mixed with surfactants or other pesticides or used along with  
23 other pesticides, and inhaled, ingested, or absorbed into the bodies of persons who  
24 used Defendants' paraquat products, were nearby while they were being used, or  
25 entered fields or orchards where they had been sprayed or areas near where there had  
26 been sprayed, was likely to cause or contribute to cause latent, cumulative, and  
27 permanent neurological damage, and the extent to which repeated exposures were  
28 likely to cause or contribute to cause clinically significant neurodegenerative disease,  
including Parkinson's disease, to develop over time and manifest long after exposure.

176. From the first date on which Defendants and those with whom they were acting in  
concert placed Defendants' paraquat products into the stream of commerce from the State of  
California through the last date on which Plaintiff Lloyd Parsons was exposed to Defendants'  
paraquat products, Defendants and those with whom they were acting in concert engaged in unfair  
or deceptive acts or practices, including but not limited to deception, fraud, false pretense, false  
promise, misrepresentation or the concealment, suppression, or omission of material facts, in

1 designing, manufacturing, and distributing paraquat for use in formulating Defendants' paraquat  
2 products for distribution for sale and use from the State of California and in designing, formulating,  
3 and distributing Defendants' paraquat products for sale and use from the State of California, in that  
4 they:

- 5 a. concealed, suppressed, or omitted to disclose that Defendants' paraquat products were  
6 designed, manufactured, formulated, and packaged such that paraquat was likely to  
7 be inhaled, ingested, and absorbed into the bodies of persons who used them, were  
8 nearby while they were being used, or entered fields or orchards where they had been  
9 sprayed or areas near where they had been sprayed;
- 10 b. concealed, suppressed, or omitted to disclose that when inhaled, ingested, or absorbed  
11 into the bodies of persons who used Defendants' paraquat products, were nearby while  
12 they were being used, or entered fields or orchards where they had been sprayed  
13 or areas near where they had been sprayed, paraquat was likely to cause or contribute  
14 to cause latent, cumulative, and permanent neurological damage, and repeated  
15 exposures were likely to cause or contribute to cause clinically significant  
16 neurodegenerative disease, including Parkinson's disease, to develop over time and  
17 manifest long after exposure;
- 18 c. concealed, suppressed, or omitted to disclose that adequate testing had not been  
19 performed to determine the extent to which exposure to paraquat was likely to occur  
20 through inhalation, ingestion, and absorption into the bodies of persons who used  
21 Defendants' paraquat products, were nearby while they were being used, or entered  
22 fields or orchards where they had been sprayed or areas near where they had been  
23 sprayed;
- 24 d. concealed, suppressed, or omitted to disclose that adequate testing had not been  
25 performed to determine the extent to which spray drift was likely to occur when  
26 Defendants' paraquat products were used, including their propensity to drift, the  
27 distance they were likely to drift, and the extent to which paraquat spray droplets were  
28 likely to enter the bodies of persons spraying or others nearby during or after spraying;
- 29 e. concealed, suppressed, or omitted to disclose that adequate testing had not been  
30 performed to determine the extent to which paraquat, when inhaled, ingested, or  
31 absorbed into the bodies of persons who used Defendants' paraquat products, were  
32 nearby while they were being used, or entered fields or orchards where they had been  
33 sprayed or areas near where they had been sprayed, was likely to cause or contribute  
34 to cause latent, cumulative, and permanent neurological damage, and the extent to  
35 which repeated exposures were likely to cause or contribute to cause clinically  
36 significant neurodegenerative disease, including Parkinson's disease, to develop over  
37 time and manifest long after exposure; and

1 f. concealed, suppressed, or omitted to disclose that adequate testing had not been  
2 performed to determine the extent to which paraquat, when formulated or mixed with  
3 surfactants or other pesticides or used along with other pesticides, and inhaled,  
4 ingested, or absorbed into the bodies of persons who used Defendants' paraquat  
5 products, were nearby while they were being used, or entered fields or orchards where  
6 they had been sprayed or areas near where they had been sprayed, was likely to cause  
or contribute to cause latent, cumulative, and permanent neurological damage, and the  
extent to which repeated exposures were likely to cause or contribute to cause  
clinically significant neurodegenerative disease, including Parkinson's disease, to  
develop over time and manifest long after exposure.

7 177. These acts and practices of Defendants and those with whom they were acting in  
8 concert in designing, manufacturing, and distributing paraquat for use in formulating Defendants'  
9 paraquat products for distribution for sale and use from the State of California and in designing,  
10 formulating, and distributing Defendants' paraquat products for sale and use from the State of  
11 California were unfair because they offended public policy, were immoral, unethical, oppressive, and  
12 unscrupulous, and caused substantial injury to consumers.

13 178. These acts and practices of Defendants and those with whom they were acting in  
14 concert in designing, manufacturing, and distributing paraquat for use in formulating Defendants'  
15 paraquat products for distribution for sale and use from the State of California and in designing,  
16 formulating, and distributing Defendants' paraquat products for sale and use from the State of  
17 California offended the clearly stated public policy of the State of California, as expressed in Cal.  
18 Const. Art. I, § I, that "[a]ll people are by nature free and independent and have inalienable rights.  
19 Among these are enjoying and defending life and liberty, acquiring, possessing, and protecting  
20 property, and pursuing and obtaining safety, happiness, and privacy."

21 179. These acts and practices of Defendants and those with whom they were acting in  
22 concert in designing, manufacturing, and distributing paraquat for use in formulating Defendants'  
23 paraquat products for distribution for sale and use from the State of California and in designing,  
24 formulating, and distributing Defendants' paraquat products for sale and use from the State of  
25 California and in designing,  
26 formulating, and distributing Defendants' paraquat products for sale and use from the State of  
27 California and in designing,

PANISH SHEA & BOYLE LLP  
11111 Santa Monica Boulevard, Suite 700  
Los Angeles, California 90025  
310.477.1700 phone • 310.477.1699 fax

1 California offended the clearly stated public policy of the State of California, as expressed in  
2 California Environmental Quality Act, Cal. Pub. Res. Code § 21000, that:

- 3 a. The maintenance of a quality environment for the people of this state now and in the  
4 future is a matter of statewide concern.
- 5 b. It is necessary to provide a high-quality environment that at all times is healthful and  
6 pleasing to the senses and intellect of man.
- 7 c. It is the intent of the Legislature that all agencies of the state government which  
8 regulate activities of private individuals, corporations, and public agencies which  
9 are found to affect the quality of the environment, shall regulate such activities so  
10 that major consideration is given to preventing environmental damage, while  
11 providing a decent home and satisfying living environment for every Californian.

12 180. These acts and practices of Defendants and those with whom they were acting in  
13 concert in designing, manufacturing, and distributing paraquat for use in formulating Defendants'  
14 paraquat products for distribution for sale and use from the State of California and in designing,  
15 formulating, and distributing Defendants' paraquat products for sale and use from the State of  
16 California were immoral and unethical, as they served only to benefit Defendants and those with  
17 whom they were acting in concert at the expense of the health of purchasers and users of Defendants'  
18 paraquat products and the public.

19 181. These acts and practices of Defendants and those with whom they were acting in  
20 concert in designing, manufacturing, and distributing paraquat for use in formulating Defendants'  
21 paraquat products for distribution for sale and use from the State of California and in designing,  
22 formulating, and distributing Defendants' paraquat products for sale and use from the State of  
23 California were likely to cause substantial injury to purchasers and users of paraquat and the public  
24 by exposing them to unnecessary risks to their health.

25 182. These acts and practices of Defendants and those with whom they were acting in  
26 concert in designing, manufacturing, and distributing paraquat for use in formulating Defendants'

1 paraquat products for distribution for sale and use from the State of California and in designing,  
2 formulating, and distributing Defendants’ paraquat products for sale and use from the State of  
3 California were likely to cause, and did cause, substantial injury to purchasers and users of paraquat  
4 and the public in that but for these acts and practices, Defendants’ paraquat products would not have  
5 been purchased for use in Oregon and persons who used them, were nearby while they was being  
6 used, or entered fields or orchards where they had been sprayed or areas near where it they been  
7 sprayed, would not have been injured by exposure to paraquat.  
8

9 183. Defendants and those with whom they were acting in concert in designing,  
10 manufacturing, and distributing paraquat for use in formulating Defendants’ paraquat products for  
11 distribution for sale and use from the State of California and in designing, formulating, and  
12 distributing Defendants’ paraquat products for sale and use from the State of California committed  
13 these acts and engaged in these practices in conscious disregard of the safety of others, including  
14 Plaintiff Lloyd Parsons.  
15

16 184. The injuries caused by these acts and practices of Defendants and those with whom  
17 they were acting in concert in designing, manufacturing, and distributing paraquat for use in  
18 formulating Defendants’ paraquat products for distribution for sale and use from the State of  
19 California and in designing, formulating, and distributing Defendants’ paraquat products for sale and  
20 use from the State of California—namely, purchasers’ monetary losses and the injuries and damages  
21 (including monetary losses) to persons who used them, were nearby while they were being used, or  
22 entered fields or orchards where they had been sprayed or areas near where they had been sprayed,  
23 including Plaintiff Lloyd Parsons—are not outweighed by any countervailing benefit to consumers  
24 or competition.  
25  
26  
27

1           185. The injuries caused by these acts and practices of Defendants and those with whom  
2 they were acting in concert in designing, manufacturing, and distributing paraquat for use in  
3 formulating Defendants’ paraquat products for distribution for sale and use from the State of  
4 California and in designing, formulating, and distributing Defendants’ paraquat products for sale and  
5 use from the State of California—namely, purchasers’ monetary losses and the injuries and damages  
6 (including monetary losses) to persons who used them, were nearby while they were being used, or  
7 entered fields or orchards where they had been sprayed or areas near where they had been sprayed,  
8 including Plaintiff Lloyd Parsons—were not reasonably avoidable; because Defendants and those  
9 with whom they were acting in concert had and failed to disclose material non□public information,  
10 consumers had no reason to anticipate the impending harm and thus avoid their injuries.

12           186. Defendants and those with whom they were acting in concert intended that purchasers  
13 of Defendants’ paraquat products, including Plaintiff Lloyd Parsons, purchase them in reliance on  
14 these unfair and deceptive acts and practices.

16           187. The facts that Defendants and those with whom they were acting in concert concealed,  
17 suppressed, or omitted to disclose were material to the decisions to purchase Defendants’ paraquat  
18 products, and would not have been purchased had these facts been disclosed.

19           188. These unfair and deceptive acts and practices of Defendants and those with whom  
20 they were acting in concert occurred in connection with their conduct of trade and commerce from  
21 the State of California.

22           189. These unfair and deceptive acts and practices of Defendants and those with whom  
23 they were acting in concert violated the California Consumer Legal Remedies Act, 1750, *et seq.*  
24

25  
26  
27  
28



1 190. Defendants and those with whom they were acting in concert committed these unfair  
2 and deceptive practices knowing they created a substantial risk of harm to Plaintiff Lloyd Parsons  
3 and others who purchased and used Defendants' paraquat products in California.

4 **G. Breach of implied warranty of merchantability**

5 191. At all relevant times, Defendants and those with whom they were acting in concert  
6 were engaged in the U.S. paraquat business.

7 192. At all relevant times, Defendants and those with whom they were acting in concert  
8 intended and expected that Defendants' paraquat products would be sold and used in the State of  
9 Oregon.

10 193. Defendants and those with whom they were acting in concert developed, registered,  
11 manufactured, distributed, and sold paraquat for use in formulating Defendants' paraquat products,  
12 and developed, registered, formulated and distributed Defendants' paraquat products for sale and use  
13 in the U.S., including Oregon.

14 194. Upon information and belief, Plaintiff used Defendants' paraquat products in Oregon  
15 repeatedly and regularly for hours at a time, resulting in the repeated, regular, and prolonged exposure  
16 of Plaintiff to paraquat.

17 195. At the time of each sale of Defendants' paraquat products that resulted in Plaintiff's  
18 exposure to paraquat, Defendants and those with whom they were acting in concert impliedly  
19 warranted that Defendants' paraquat products were of merchantable quality, including that they were  
20 fit for the ordinary purposes for which such goods were used, pursuant to section 2-314 of the  
21 Uniform Commercial Code.

22 196. Defendants and those with whom they were acting in concert breached this warranty  
23 as to each sale of Defendants' paraquat products that resulted in Plaintiff' exposure to paraquat, in  
24

1 that Defendants’ paraquat products were not of merchantable quality because they were not fit for  
2 the ordinary purposes for which such goods were used, and in particular:

- 3 a. they were designed, manufactured, formulated, and packaged such that paraquat was  
4 likely to be inhaled, ingested, and absorbed into the bodies of persons who used them,  
5 were nearby while they were being used, or entered fields or orchards where they had  
6 been sprayed or areas near where they had been sprayed; and
- 7 b. when inhaled, ingested, or absorbed into the bodies of persons who used Defendants’  
8 paraquat products, were nearby while they were being used, or entered fields or  
9 orchards where they had been sprayed or areas near where they had been sprayed,  
10 paraquat was likely to cause or contribute to cause latent, cumulative, and permanent  
11 neurological damage, and repeated exposures were likely to cause or contribute to  
12 cause clinically significant neurodegenerative disease, including Parkinson’s disease,  
13 to develop over time and manifest long after exposure.

14 **COUNT 1 – STRICT PRODUCT LIABILITY DESIGN DEFECT**  
 15 **PLAINTIFF v. DEFENDANTS SCPLLC AND SAG**

16 197. Plaintiff incorporates in this Count by reference paragraphs 1 through 196 of this  
17 Complaint.

18 198. As a direct and proximate result of the defective and unreasonably dangerous  
19 condition of Defendants’ paraquat products, Plaintiff Lloyd Parsons developed Parkinson’s disease;  
20 has suffered severe and permanent physical pain, mental anguish, and disability, and will continue  
21 to do so for the remainder of his life; has suffered the loss of a normal life and will continue to do so  
22 for the remainder of his life; has lost income that he otherwise would have earned and will continue  
23 to do so for the remainder of his life; and has incurred reasonable expenses for necessary medical  
24 treatment and will continue to do so for the remainder of his life.

25 **COUNT 2 – STRICT PRODUCT LIABILITY – FAILURE TO WARN**  
 26 **PLAINTIFF v. DEFENDANTS SCPLLC AND SAG**

27 199. Plaintiff incorporates in this Count by reference paragraphs 1 through 196 of this  
28 Complaint.

PANISH SHEA & BOYLE LLP  
 11111 Santa Monica Boulevard, Suite 700  
 Los Angeles, California 90025  
 310.477.1700 phone • 310.477.1699 fax

1 200. As a direct and proximate result of the lack of adequate directions for the use of and  
2 warnings about the dangers of Defendants’ paraquat products, Plaintiff Lloyd Parsons developed  
3 Parkinson’s disease; has suffered severe and permanent physical pain, mental anguish, and disability,  
4 and will continue to do so for the remainder of his life; has suffered the loss of a normal life and will  
5 continue to do so for the remainder of his life; has lost income that he otherwise would have earned  
6 and will continue to do so for the remainder of his life; and has incurred reasonable expenses for  
7 necessary medical treatment and will continue to do so for the remainder of his life.  
8

9 **COUNT 3 – NEGLIGENCE**  
10 **PLAINTIFF v. DEFENDANTS SCPLLC AND SAG**

11 201. Plaintiff incorporates in this Count by reference paragraphs 1 through 196 of this  
12 Complaint.

13 202. As a direct and proximate result of the negligence of Defendants and those with whom  
14 they were acting in concert, Plaintiff Lloyd Parsons developed Parkinson’s disease; has suffered  
15 severe and permanent physical pain, mental anguish, and disability, and will continue to do so for  
16 the remainder of his life; has suffered the loss of a normal life and will continue to do so for the  
17 remainder of his life; has lost income that he otherwise would have earned and will continue to do  
18 so for the remainder of his life; and has incurred reasonable expenses for necessary medical treatment  
19 and will continue to do so for the remainder of his life.  
20

21 **COUNT 4 – PUBLIC NUISANCE**  
22 **PLAINTIFF v. DEFENDANTS SCPLLC AND SAG**

23 203. Plaintiff incorporates in this Count by reference paragraphs 1 through 196 of this  
24 Complaint.

25 204. As a direct and proximate result of the public nuisance created by Defendants and  
26 those with whom they were acting in concert, Plaintiff Lloyd Parsons developed Parkinson’s disease;  
27

1 has suffered severe and permanent physical pain, mental anguish, and disability, and will continue  
2 to do so for the remainder of his life; has suffered the loss of a normal life and will continue to do so  
3 for the remainder of his life; has lost income that he otherwise would have earned and will continue  
4 to do so for the remainder of his life; and has incurred reasonable expenses for necessary medical  
5 treatment and will continue to do so for the remainder of his life.

6 **COUNT 5 – OREGON UNLAWFUL TRADE PRACTICES ACT & CALIFORNIA**  
7 **CONSUMER LEGAL REMEDIES ACT**  
8 **PLAINTIFF v. DEFENDANTS SCPLLC AND SAG**

9 205. Plaintiff incorporates in this Count by reference paragraphs 1 through 196 of this  
10 Complaint.

11 206. As a direct and proximate result of the violations of the Oregon Unlawful Trade  
12 Practices Act and the California Consumer Legal Remedies Act by Defendants and those with whom  
13 they were acting in concert, Plaintiff Lloyd Parsons developed Parkinson’s disease; has suffered  
14 severe and permanent physical pain, mental anguish, and disability, and will continue to do so for  
15 the remainder of his life; has suffered the loss of a normal life and will continue to do so for the  
16 remainder of his life; has lost income that he otherwise would have earned and will continue to do  
17 so for the remainder of his life; and has incurred reasonable expenses for necessary medical treatment  
18 and will continue to do so for the remainder of his life.

19 **COUNT 6 – BREACH OF IMPLIED WARRANTY OF MERCHANTABILITY**  
20 **PLAINTIFF v. DEFENDANTS SCPLLC AND SAG**

21 207. Plaintiff incorporates in this Count by reference paragraphs 1 through 196 of this  
22 Complaint.

23 208. As a direct and proximate result of the breaches of the implied warranty of  
24 merchantability by Defendants and those with whom they were acting in concert, Plaintiff Lloyd  
25 Parsons developed Parkinson’s disease; has suffered severe and permanent physical pain, mental  
26

1 anguish, and disability, and will continue to do so for the remainder of his life; has suffered the loss  
2 of a normal life and will continue to do so for the remainder of his life; has lost income that he  
3 otherwise would have earned and will continue to do so for the remainder of his life; and has incurred  
4 reasonable expenses for necessary medical treatment and will continue to do so for the remainder of  
5 his life.

6 **COUNT 7 – STRICT PRODUCT LIABILITY – DESIGN DEFECT**  
7 **PLAINTIFF v. DEFENDANTS CHEVRON U.S.A., INC.**

8 209. Plaintiff incorporates in this Count by reference paragraphs 1 through 196 of this  
9 Complaint.

10 210. As a direct and proximate result of the defective and unreasonably dangerous  
11 condition of Defendants’ paraquat products, Plaintiff Lloyd Parsons developed Parkinson’s disease;  
12 has suffered severe and permanent physical pain, mental anguish, and disability, and will continue  
13 to do so for the remainder of his life; has suffered the loss of a normal life and will continue to do so  
14 for the remainder of his life; has lost income that he otherwise would have earned and will continue  
15 to do so for the remainder of his life; and has incurred reasonable expenses for necessary medical  
16 treatment and will continue to do so for the remainder of his life.

17 **COUNT 8 – STRICT PRODUCT LIABILITY – FAILURE TO WARN**  
18 **PLAINTIFF v. DEFENDANTS CHEVRON U.S.A., INC.**

19 211. Plaintiff incorporates in this Count by reference 1 through 196 of this Complaint.

20 212. As a direct and proximate result of the lack of adequate directions for the use of and  
21 warnings about the dangers of Defendants’ paraquat products, Plaintiff John developed Parkinson’s  
22 disease; has suffered severe and permanent physical pain, mental anguish, and disability, and will  
23 continue to do so for the remainder of his life; has suffered the loss of a normal life and will continue  
24 to do so for the remainder of his life; has lost income that he otherwise would have earned and will  
25  
26

PANISH SHEA & BOYLE LLP  
11111 Santa Monica Boulevard, Suite 700  
Los Angeles, California 90025  
310.477.1700 phone • 310.477.1699 fax

1 continue to do so for the remainder of his life; and has incurred reasonable expenses for necessary  
2 medical treatment and will continue to do so for the remainder of his life.

3 **COUNT 9 – NEGLIGENCE**  
4 **PLAINTIFF v. DEFENDANTS CHEVRON U.S.A., INC.**

5 213. Plaintiff incorporates in this Count by reference paragraphs 1 through 196 of this  
6 Complaint.

7 214. As a direct and proximate result of the negligence of Defendants and those with whom  
8 was acting in concert, Plaintiff Lloyd Parsons developed Parkinson’s disease; has suffered severe  
9 and permanent physical pain, mental anguish, and disability, and will continue to do so for the  
10 remainder of his life; has suffered the loss of a normal life and will continue to do so for the remainder  
11 of his life; has lost income that he otherwise would have earned and will continue to do so for the  
12 remainder of his life; and has incurred reasonable expenses for necessary medical treatment and will  
13 continue to do so for the remainder of his life.  
14

15 **COUNT 10 – PUBLIC NUISANCE**  
16 **PLAINTIFF v. DEFENDANTS CHEVRON U.S.A., INC.**

17 215. Plaintiff incorporates in this Count by reference paragraphs 1 through 196 of this  
18 Complaint.

19 216. As a direct and proximate result of the public nuisance created by Defendants and  
20 those with whom they were acting in concert, Plaintiff Lloyd Parsons developed Parkinson’s disease;  
21 has suffered severe and permanent physical pain, mental anguish, and disability, and will continue  
22 to do so for the remainder of his life; has suffered the loss of a normal life and will continue to do so  
23 for the remainder of his life; has lost income that he otherwise would have earned and will continue  
24 to do so for the remainder of his life; and has incurred reasonable expenses for necessary medical  
25 treatment and will continue to do so for the remainder of his life.  
26

1                   **COUNT 11 – OREGON UNLAWFUL TRADE PRACTICES ACT & CALIFORNIA**  
2   **CONSUMER LEGAL REMEDIES ACT**  
3   **PLAINTIFF v. DEFENDANTS CHEVRON U.S.A., INC.**

4                   217. Plaintiff Lloyd Parsons incorporates in this Count by reference paragraphs 1 through  
5 196 of this Complaint.

6                   218. As a direct and proximate result of the violations of the Oregon Unlawful Trade  
7 Practices Act and the California Consumer Legal Remedies Act by Defendants and those with whom  
8 they were acting in concert, Plaintiff Lloyd Parsons developed Parkinson’s disease; has suffered  
9 severe and permanent physical pain, mental anguish, and disability, and will continue to do so for  
10 the remainder of his life; has suffered the loss of a normal life and will continue to do so for the  
11 remainder of his life; has lost income that he otherwise would have earned and will continue to do  
12 so for the remainder of his life; and has incurred reasonable expenses for necessary medical treatment  
13 and will continue to do so for the remainder of his life.

14                   **COUNT 12 – BREACH OF IMPLIED WARRANTY OF MERCHANTABILITY**  
15   **PLAINTIFF v. DEFENDANTS CHEVRON U.S.A., INC.**

16                   219. Plaintiff incorporates in this Count by reference paragraphs 1 through 196 of this  
17 Complaint.

18                   220. As a direct and proximate result of the breaches of the implied warranty of  
19 merchantability by Defendants and those with whom they were acting in concert, Plaintiff Lloyd  
20 Parsons developed Parkinson’s disease; has suffered severe and permanent physical pain, mental  
21 anguish, and disability, and will continue to do so for the remainder of his life; has suffered the loss  
22 of a normal life and will continue to do so for the remainder of his life; has lost income that he  
23 otherwise would have earned and will continue to do so for the remainder of his life; and has incurred  
24 reasonable expenses for necessary medical treatment and will continue to do so for the remainder of  
25 his life.

PANISH SHEA & BOYLE LLP  
11111 Santa Monica Boulevard, Suite 700  
Los Angeles, California 90025  
310.477.1700 phone • 310.477.1699 fax

**VIII. Plaintiff's prayer for relief**

221. Plaintiff Lloyd Parsons prays that this Court enter judgment in his favor and against Defendants SYNGENTA CROP PROTECTION LLC, SYNGENTA AG, and CHEVRON U.S.A., INC., jointly and severally for compensatory damages in an amount greater than \$75,000.00 plus costs of suit, severally as to each Defendants for punitive damages in an amount sufficient to punish it and encourage it and others from similar conduct, for reasonable attorney's fees, and for such further relief as is just and appropriate in the circumstances.

DATED: April 30, 2021

PANISH SHEA & BOYLE LLP

By:   
Peter L. Kaufman

Robert J. Mongeluzzi\*  
Lawrence R. Cohan\*  
Jeffrey P. Goodman\*  
Joshua C. Cohan\*  
Samuel B. Dordick\*  
**SALTZ MONGELUZZI &  
BENDESKY P.C.**  
One Liberty Place  
1650 Market Street, 52nd Floor  
Philadelphia, Pennsylvania 19103  
Tel: (215) 496-8282  
rmongeluzzi@smbb.com  
lcohan@smbb.com  
jgoodman@smbb.com  
jcohan@smbb.com  
sdordick@smbb.com

Mark A. DiCello\*  
Mark M. Abramowitz\*  
**DiCELLO LEVITT GUTZLER LLC**  
7556 Mentor Avenue  
Mentor, Ohio 44060  
Tel: (440) 953-8888  
madicello@dicellolevitt.com  
mabramowitz@dicellolevitt.com

Adam J. Levitt\*  
Amy E. Keller\*

PANISH SHEA & BOYLE LLP  
11111 Santa Monica Boulevard, Suite 700  
Los Angeles, California 90025  
310.477.1700 phone • 310.477.1699 fax

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28



PANISH SHEA & BOYLE LLP

11111 Santa Monica Boulevard, Suite 700  
Los Angeles, California 90025  
310.477.1700 phone • 310.477.1699 fax

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**DiCELLO LEVITT GUTZLER LLC**  
Ten North Dearborn Street, Sixth Floor  
Chicago, Illinois 60602  
Tel: (312) 214-7900  
alevitt@dicellolevitt.com  
akeller@dicellolevitt.com

C. Calvin Warriner III\*  
Katherine A. Kiziah\*  
**SEARCY DENNEY SCAROLA  
BARNHART & SHIPLEY, PA**  
2139 Palm Beach Lakes Blvd.  
West Palm Beach, Florida 33409  
ccw@searcylaw.com  
kkiziah@searcylaw.com

*Counsel for Plaintiff*


\*Applications for admission *pro hac vice* to be filed

**DEMAND FOR JURY TRIAL**

Plaintiff hereby demands a trial by jury as to all causes of action.

DATED: April 30, 2021

PANISH SHEA & BOYLE LLP

By:   
\_\_\_\_\_

Peter L. Kaufman

PANISH SHEA & BOYLE LLP  
11111 Santa Monica Boulevard, Suite 700  
Los Angeles, California 90025  
310.477.1700 phone • 310.477.1699 fax

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28